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Nomenclature 
 
Amino acids are given in the one-letter code (e. g. K for lysine), whereby X is a 
placeholder for any amino acid (e. g. PPX for proline-proline-amino acid).  
The configuration at the stereocenter of an amino acid is given according to Cahn-
Ingold-Prelog priority rules (e. g. (R/S)-lysine) instead of using the historically evolved 
D/L configuration derived from the Fischer projection. 
Amino acid exchanges are indicated by naming the original amino acid followed by its 
position in the protein and the new amino acid (e. g. EpmA_A298G: alanine in position 
289 of EpmA is replaced by glycine). 
N-terminal and C-terminal affinity tags are placed corresponding to their position in 
relation to the protein (e. g. His6_epmA or efp_His6). 
The bacterial origin of a gene or protein is abbreviated and subscripted (e. g. efpE.c., 
EF-PB.s.). Deletions of genes as well as the mass difference between unmodified and 
modified EF-P are marked with Δ.  
P68 and P69 name the two different peptide antibodies for EF-P from diverse bacteria. 
Their names are derived from the synthesized peptides no. 1612068 and 1612069 
(Eurogentec numbering), respectively. 
The incorrect but widely used biological unit m/v% (mass/volume percentage) is 
renounced. 
Antibiotic resistances are indicated by the abbreviated antibiotic followed by 
superscripted ‘R’ (e. g. CmR, KanR), whereby sensitivity to the certain antibiotic is 
indicated by superscripted ‘S’ (e. g. KanS).  
If not otherwise stated, tests were conducted in biological replicates of at least three 
individual measurements and are presented by mean and standard error (s.e.m.).  
Radioactively labeled compounds are marked with a star (e. g. ATP* for [α-32P]-ATP). 
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Summary 
Protein translation is a non-uniform process, whereby especially proline-containing 
motifs lead to ribosome stalling events. Elongation factor P (EF-P) rescues the 
ribosome by stimulation of peptidyl transfer. The four known subgroups of bacterial 
EF-Ps either require post-translational modification (PTM) established by 
EpmABC/EarP/YmfI or are functional without PTM. In Escherichia coli, the 
aminomutase EpmB converts (S)-α-lysine into (R)-β-lysine, which is subject to a two-
step reaction catalyzed by lysyl-tRNA synthetase paralog EpmA. First, (R)-β-lysyl-
adenylate is formed, from which the β-lysyl moiety is subsequently transferred to the 
ε-amino group of lysine 34 of EF-P.  
This thesis focuses on the interplay of EF-P and EpmA which ensures EF-P 
functionality in vivo and was used to modify EF-P with seven unnatural substrates in 
vitro. To detect PTM status two universal peptide antibodies, nonselective for the 
bacterial origin of EF-P, were generated and three subtypes of one-dimensional 
isoelectric focusing were established (native/denaturating horizontal, vertical). EpmA 
and EF-P protein copy numbers indicated balanced coordination to ensure outright 
modification status of EF-P during all growth phases, but no mutual regulation. EpmA’s 
donor substrate promiscuity was pinpointed to permit C6 scaffolds with at least an 
amino group at α- ((R/S)-α-lysine, 5-hydroxy-(S)-α-lysine), β- ((R/S)-β-lysine, (R)-3-
aminocapronic acid) or ε-position (6-aminocapronic acid). In addition, EpmA variant 
A298G enabled modification of EF-P with (S)-α-ornithine. For the first time, known 
natural PTMs of EF-P were expanded by seven synthetic PTMs. In vitro transcription 
translation assay demonstrated superiority of (R)-β-lysylation in ribosome rescue, 
explaining its evolutionary selection. Modification of EF-P with (S)-α-lysine was 
successfully achieved in vivo, when (R)-β-lysine synthesis was impeded (E. coli 
ΔepmB) and epmA(_A298G) overexpressed. 
In Bacillus subtilis, the ratio of unmodified-to-modified EF-P varied over time. Out of 13 
tested aminotransferase genes dat, epsN, gsaB, ilvK and yhdR are potentially involved 
in the yet unsolved modification pathway.  
In summary, the present work not only provides new biochemical insights into the 
functionalization of EF-P, but also paves the way to modify proteins post-translationally 
using EpmA. 
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Zusammenfassung 
Die Translation von Proteinen ist kein gleichförmiger Prozess. Besonders bei 
Polyprolinmotiven treten Verzögerungen des Ribosoms auf. Hier übernimmt 
Elongationsfaktor P (EF-P) eine helfende Funktion und stimuliert den Peptidyltransfer. 
Die vier bekannten Gruppen von bakteriellen EF-P benötigen entweder 
posttranslationale Modifikation (PTM) durch EpmABC/EarP/YmfI, oder sind ohne PTM 
funktional. In Escherichia coli wandelt die Aminomutase EpmB (S)-α-Lysin in (R)-β-
Lysin um. Ein Paralog der Lysyl-tRNA-Synthetase, EpmA, katalysiert die folgende 
zweistufige Reaktion. Erst wird (R)-β-Lysyladenylat gebildet, dessen β-Lysylgruppe 
dann auf die ε-Aminogruppe von Lysin 34 von EF-P übertragen wird.  
Diese Dissertation widmet sich dem Zusammenspiel von EF-P und EpmA. Dieses stellt 
in vivo die Funktion von EF-P sicher, in vitro erlaubt es die Modifikation von EF-P mit 
sieben unnatürlichen Substraten. Zur Detektion des PTM Status wurden zwei 
universelle Peptidantikörper etabliert, die EF-P unabhängig von dessen bakterieller 
Herkunft detektieren, sowie drei Formen der eindimensionalen Isoelektrischen 
Fokussierung (nativ/denaturierend horizontal, vertikal). Die Kopienzahlen von EpmA 
und EF-P sind aufeinander abgestimmt, um vollständige Modifikation von EF-P in allen 
Wachstumsphasen sicherzustellen. Sie regulieren sich aber nicht gegenseitig. Die 
Promiskuität von EpmA erlaubt Donorsubstrate mit C6-Ketten, die zumindest eine 
Aminogruppe in α- ((R/S)-α-Lysin, 5-Hydroxy-(S)-α-lysin), β- ((R/S)-β-Lysin, (R)-3-
Aminohexansäure) oder ε-Position (6-Aminohexansäure) haben. Zusätzlich ermöglicht 
die Enzymvariante EpmA_A298G (S)-α-Ornithylierung von EF-P. Erstmals konnten so 
die natürlichen PTMs von EF-P um sieben synthetische PTMs erweitert werden. In 
vitro Transkriptions/Translations-Assays zeigten die wirkungsvollste Ribosomen-
rettung bei (R)-β-lysyliertem EF-P, was dessen evolutionäre Auswahl erklärt. In vivo 
gelang die Modifikation von EF-P mit (S)-α-Lysin, wenn die Fähigkeit zur (R)-β-
Lysinsynthese fehlte (E. coli ΔepmB) und epmA(_A298G) überexprimiert wurde.  
In Bacillus subtilis variiert das Verhältnis von unmodifiziertem zu modifiziertem EF-P. 
Von 13 untersuchten Genen, die Aminotransferasen kodieren, sind dat, epsN, gsaB, 
ilvK und yhdR möglicherweise am ungeklärten Modifikationsweg beteiligt. 
Zusammengefasst liefert die vorliegende Arbeit nicht nur neue biochemische 
Einsichten in die Funktionalisierung von EF-P, sondern eröffnet auch einen neuen 
Weg, Proteine mittels EpmA posttranslational zu modifizieren.  
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1 Introduction 
1.1 Translation as checkpoint for protein production 
In all domains of life, the fundamental step of protein synthesis presets cellular 
proteome composition and quality. Coordinated interplay of several cellular 
compounds is necessary for conversion of a gene into a functional protein. For 
transcription RNA polymerase, transcription factors and RNA nucleotides are 
employed to form the pool of messenger RNA. The latter is further processed at the 
ribosome to translate it by the help of charged tRNA (harboring the anticodon triplets 
of the genetic code), several translation factors and GTP into a functional protein 
(Figure 1). The ribosome serves as the central machinery of mRNA-to-protein 
translation and in bacteria, it consists of three rRNAs (16S, 23S, 5S) and 52 ribosomal 
proteins itself [2]. Ribosome concentration increases with increasing cell size leading 
to the conclusion that the ~10,000 ribosomes/cells exclude ribosome availability 
limitation [2]. This is also reflected in the stable active ribosome fraction of 80 % [3].  
All three steps of translation - namely initiation, elongation and termination - but also 
the co-translational folding are checkpoints on the way to protein synthesis that finally 
ensures protein homeostasis or stress adaptation. They all aim to work together for 
optimal protein amount and quality. It is known that transcription and translation speed 
are coordinated as their rates are equivalent [3]. During initiation the ribosome selects 
and binds the mRNA and occupies the ribosome binding site (RBS) at the start of the 
open reading frame (ORF). At this stage, the control point is mainly RBS accessibility 
supervised by secondary mRNA structures which are induced by protein-, RNA-, 
metabolite-, and temperature variations [4]. Translation elongation implies aminoacyl-
tRNA (aa-tRNA) selection, peptide bond formation in the peptidyl transferase center 
(PTC) and tRNA/mRNA translocation (Figure 1) [5]. After completed translation of the 
mRNA into a polypeptide chain, the latter is released from the ribosome which 
dissociates into its subunits (termination and ribosome recycling) [4]. 
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Figure 1: Ribosome during translation of mRNA to form the nascent polypeptide chain. The 
cartoon is derived from [6]. PTC: peptidyl transferase center. 
This thesis focuses on the step of translation elongation, whereby rapidly synthesized 
stretches can be interrupted by translational pauses, making translation elongation a 
non-uniform process. In average, 12 to 21 amino acids per second are connected in 
the widely used laboratory organism Escherichia coli but as the translation rate is not 
uniform, it depends on various factors such as secondary structure elements of the 
mRNA, tRNA availability, rare codon usage, interactions between ribosome and 
nascent polypeptide (stalling peptides) and not least of amino acid nature [3, 5, 7]. It is 
calculated that one aminoacyl-tRNA synthetase (aaRS) aminoacylates 10 cognate 
tRNAs per second, leading to a tRNA pool with 75 - 90 % charging level on average 
[2]. Availability of low abundant cognate aa-tRNAs as well as codon choice are factors 
that can influence local translation elongation rates [4]. For example, there are hints 
that rare codons are found between protein domains to downregulate translation speed 
which provides a time delay for correct folding [8, 9]. Translation of a mRNA strand is 
newly initiated before the ribosome completes translation of the ORF which leads to 
polysome formation and is reflected by the ratio of ~540 protein copies per one mRNA 
copy in E. coli [10]. Bremer et al. reported that increasing growth rates lead to less 
space between one ribosome on the mRNA and the following one, namely it is reduced 
from 120 to 60 nucleotides during exponential growth [2]. These “logistic demands” 
reflect the necessity for high accuracy and smooth progression of translation 
elongation. The identity of the peptidyl-tRNA in the peptidyl site (P-site) as well as aa-
tRNA in the aminoacyl site (A-site) can contribute to decreased elongation rates 
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because donor and acceptor substrate influence peptidyl transfer [11]. Regarding 
these amino acid structure effects especially proline sticks out due to rigidity of its 
pyrrolidine ring. The challenge to translate polyproline sequences arises from poor 
accommodation of the prolyl-tRNA, the retarded rate of peptide bond formation at 
proline residues and clashes between the nascent polyproline chain and the exit tunnel 
[12–14]. This leads to high dependency of elongation speed on the amino acid context 
surrounding a diproline motif. Explicitly, strong ribosome stalling occurs for example at 
triproline and D/A-PP or PP-W/D/N/G motifs [15].  
To ensure protein homeostasis and bacterial fitness, specialized translation elongation 
factors are recruited to the ribosome to facilitate peptide bond formation between 
prolines in bacteria (translation elongation factor P (EF-P), [16]) as well as in 
eukaryotes (eukaryotic translation initiation factor 5A (eIF5A), [17]), respectively.  
To summarize, translation elongation is a non-uniform process. Especially polyproline 
containing motifs lead to ribosome stalling that requires relief by a specialized 
translation elongation factor.  
1.2 Bacterial translation elongation factors 
Translation elongation factors EF-Tu (thermo unstable), EF-Ts (thermo stable) and 
EF-G support translation independent of the motif to be translated, whereby EF-P is 
especially recruited to paused ribosomes.  
Charged tRNAs (aa-tRNAs) form the ternary complex with EF-Tu and GTP and are 
subsequently delivered to the ribosome [5]. The ternary complex with the cognate aa-
tRNA interacts with the mRNA codon exposed in the A-site of the ribosome. Here, 
EF-Tu catalyzes hydrolysis of GTP and dissociates from the ribosome. At this stage, 
EF-Ts acts as the guanine nucleotide exchange factor for EF-Tu. This leads to a 
change in conformation of the complex and enables the aa-tRNA to align in the A-site 
and to interact with the nascent peptide chain in the P-site [4]. It is shown for 
corporation of proline into the nascent peptide chain that the slowest step is performed 
at the PTC after GTP hydrolysis of EF-Tu [13].  
Another elongation factor, EF-G, catalyzes tRNA-mRNA translocation under GTP 
hydrolysis. The peptidyl-tRNA is moved from A- to P-side and subsequently, 
deacylated tRNA is repositioned to the exit site (E-site) [5]. 
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In contrast to EF-Tu and EF-G, EF-P is not catalyzing global steps during the protein 
translation but is specialized for relief of ribosome pausing that is caused by stalling 
motifs. EF-P is conserved among all bacteria whereby the evolutionary origin is linked 
to valyl-tRNA synthetase (ValS), which contains PPP in its active site and is essential 
in all bacteria [18]. EF-P is particularly required in phases of high translation initiation 
rates that entail the danger of ribosome queuing at PPX motifs [19]. 270 proteins from 
E. coli (total >4000) contain PPP or PPG, whereby transcription factors, metabolic 
proteins and transporters are more frequently found than basal proteins [20]. It was 
shown that several other stalling motifs have been selected against, except for PP(X) 
motifs [21]. EF-P was crystallized (Thermus thermophilus [22], in complex with a 
ribosome [23]; E. coli, in complex with EpmA [24]) and thereby shown to contain three 
β-barrel domains (I, II, III) that are arranged in L-shape and exhibit a negatively charged 
surface (Figure 2) [22]. N-terminal domain I contains a conserved positive residue at 
its tip [22].  
 
Figure 2: Structure of EF-P. The bacterial elongation factor contains three domains. β3/β4 loop 
contains the conserved tip residue that is post-translationally modified. The crystal structure is 
derived from E. coli [24]. 
EF-P spans both ribosomal subunits 30S and 50S and binds between peptidyl-tRNA 
P-site and the E-site [23]. Stimulation of the peptide bond formation requires functional 
EF-P reaching with the conserved residue at the tip of EF-P into the PTC [12, 23]. For 
the vast majority of bacteria it was shown that EF-P needs to be post-translationally 
modified for full functionality [16, 25]. By that, EF-P stabilizes the peptidyl-Pro-tRNA, 
decreases the activation energy by ~2.5 kcal/mol and entropically stimulates peptide 
bond formation [12]. The highly abundant polyproline motifs lead to importance of EF-P 
for proper protein synthesis in bacterial strains in general but also in pathogens.  
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1.3 Strategies for post-translational modification of EF-P 
Bacteria, eukaryotes and archaea have evolved several distinct ways to post-
translationally modify their EF-P (e/aIF5A), whereby they all have in common that the 
central amino acid residue of the loop between β-strands 3 and 4 (β3/β4 loop) is the 
position of modification. It leads to a prolongation of the residue that is now able to 
reach into the PTC and thereby stimulates peptide bond formation between prolines 
[12].  
Translation initiation factor 5A, the ortholog of EF-P in eukaryotes, is modified post-
translationally in a two-step process. Deoxyhypusine synthase (DHS) attaches the 4-
aminobutyl moiety of spermidine to a conserved lysine residue. Subsequently, 
deoxyhypusine hydroxylase (DOHH) hydroxylates the PTM to convert lysine into 
hypusine (Nε-(4-amino-2-hydroxybutyl)-lysine) [26–29]. PTM of aIF5A is similar, but 
not as detailed studied as for eIF5A [30, 31].  
In 2010 it was published that E. coli and other γ-proteobacteria modify the conserved 
K34 of EF-P with (R)-β-lysine (Figure 3) [19, 32]. The conserved residue is embedded 
in the signature sequence PGKG. The substrate of modification is produced from the 
proteinogenic amino acid lysine ((S)-α-lysine) catalyzed by aminomutase EpmB. 
Subsequently, (R)-β-lysine is ligated to EF-P by EpmA and K34 is hydroxylated by 
EpmC [19, 33]. The detailed mechanism is presented in chapter 1.4.   
In 2016, the first PTM of EF-P from a Gram-positive bacterium was published. 
Bacillus subtilis EF-P was shown to have a 5-aminopentanol residue attached to K32 
[34]. The latter lays in the corresponding signature motif KPGKG with the second lysine 
being modified [35]. 5-aminopentanolation is structurally akin to (R)-β-lysylation as well 
as to the hypusination observed in eukaryotes (eIF5A). Nevertheless, the modification 
pathway in B. subtilis and Firmicutes seems to be more complex and is not fully 
understood to date. Known is, that YmfI catalyzes the last step of modification, the 
conversion of 5-aminopentanone to 5-aminopentanol at EF-P and is found in 4.5 % of 
bacteria [35]. How and which precursor is transferred to K32 remains elusive. 
Nevertheless, Witzky et al. proposed that ynbB and gsaB are required in addition to 
ymfI [36]. 
Introduction 
6 
 
 
Figure 3: Post-translational modifications of EF-P in bacteria. The conserved tip residue (lysine 
or arginine) is modified by the help of different PTM systems.  
By contrast, the group of bacteria with ring structured PTM stands out. β-proteobacteria 
and some γ-proteobacteria including Pseudomonas mono-rhamnosylate EF-P at the 
conserved residue R32 [37]. Here, the sequence background of the β3/β4 loop is more 
variable than found for other EF-P subfamilies but proline is excluded at -2 position to 
the central arginine [38]. These 9 % of bacteria encode earP as their EF-P modification 
enzyme which rhamnosylates EF-P by N-linked glycosylation [37, 39–41]. The donor 
substrate for the reaction, dTDP-β-L-rhamnose, is produced in the RmlABCD pathway. 
In this study, Shewanella oneidensis is chosen as model organism to represent the 
group of EF-P modifiers via the EarP pathway.  
Recently a whole new clade of bacteria was published that encode EF-P not being 
post-translationally modified [35]. Instead, structure analysis revealed the palindromic 
consensus sequence PGKGP to stabilize the loop due to the rigidity of the two 
bracketing prolines [35]. The central K32 was shown to enable functionality of EF-P by 
its positively charged side chain, as replacement by arginine kept the ribosome rescue 
ability of EF-P. This unique subfamily is formed by 11 % of bacteria, including 
predominantly Actinobacteria but also Flavobacterium and Campylobacter species 
[35].  
In total, ~40 % of bacteria are known to post-translationally modify their EF-Ps. They 
all have in common that positively charged amino acids (either lysine or arginine) are 
modified in a very specific and unusual way. (R)-β-lysylation, 5-aminopentanolation 
and N-linked glycosylation were first discovered on EF-P, so on the one hand, these 
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evolutionary events seem to be quite unique strategies of protein functionalization and 
on the other hand, several independent ways to functionalize EF-P at the ribosome are 
possible. Only around one half of bacterial EF-Ps is solved regarding their PTM and/or 
modification enzymes. Therefore, study on EF-P is not complete. Especially poorly 
studied strains require specialized culture conditions and additional expertise. For 
those bacteria, EF-P detection tools, which lay the foundation for their research, remain 
elusive. Among them is a universal antibody for EF-P which is sensitive and specific 
for a preferably large group of bacteria ranging from Gram-negative to Gram-positive 
bacteria of different phyla. 
1.4 EF-P modification pathway in E. coli 
The most abundant - and for this thesis central - modification is (R)-β-lysylation of K34 
by the help of modification enzymes EpmABC. This pathway that is utilized by 26 - 
28 % of all bacteria [19, 37], including E. coli and most other γ-proteobacteria, is 
depicted in Figure 4.  
 
Figure 4: Modification pathway of EF-P by EpmABC. Aminomutase EpmB transfers the 
proteinogenic amino acid (S)-α-lysine into (R)-β-lysine. Subsequently, a two-step reaction is 
catalyzed by EpmA: First, (R)-β-lysine as donor substrate is activated by hydrolysis of ATP. 
Second step is the ligation of (R)-β-lysyl-AMP to K34 of EF-P under release of AMP (EF-PRβlys). 
The now functional EF-P is further hydroxylated at K34 by EpmC (EF-Pmod). 
The L-lysine 2,3-aminomutase EpmB (YjeK) provides the natural substrate for EpmA 
(YjeA, GenX, EF-P – (R)-β-lysine ligase, PDB: 3A5Y/Z [24]), as it isomerizes (S)-α-
Introduction 
8 
 
lysine to form (R)-β-lysine using a radical mechanism [42]. EpmB requires S-adenosyl 
methionine (SAM), a [4Fe-4S] cluster and pyridoxal 5’-phosphate (PLP) [42]. EpmA 
catalyzes the central two-step reaction that involves activation of (R)-β-lysine to form 
the high-energy aminoacyl-adenylate (R)-β-lysyl-AMP which is subsequently cleaved 
in a thermodynamically favorable reaction to condensate the activated amino acid with 
EF-P as acceptor. EpmC (EF-P hydroxylase, YfcM, PDB: 4PDN [43]) finally 
hydroxylates EF-P [33]. This last step is not essential for EF-P’s functionality [16, 18, 
20].   
It is widely accepted that deletion of efp, epmA or epmB results in similar phenotypes. 
At first glance this seems to be obvious because either epmA or epmB deletion leads 
to EF-P in the unfunctional, unmodified form and phenotypes are often similar to global 
absence of efp. Nevertheless, a detailed look at this subject reveals a divergent 
situation in the cell whether the EF-P modification pathway is impaired, EF-P is forced 
to be in the unmodified state (EF-P_K34A) or EF-P lacks completely [44, 45]. 
Moreover, there are situations reported where EF-P in the unmodified form seems to 
have an advantageous effect [46]. Therefore, it is necessary to analyze E. coli ΔepmB 
more closely regarding the modification status of EF-P in vivo, as in this strain (R)-β-
lysine is unavailable and the natural modification can not be established.  
Of all bacterial modification enzymes known to date, EpmA stands out due to its 
relevance in the most commonly used laboratory bacterium, the wide abundance in 
bacterial species in general and its central role within the PTM pathway of EF-P as it 
catalyzes both important reaction steps.  
1.5 EpmA, a representative of lysyl-tRNA synthetase class II 
In all domains of life aaRSs play a central role in protein expression as they catalyze 
the esterification of their cognate amino acids to the hydroxyl group at the 3’ end of the 
corresponding tRNAs (Figure 5, upper part) [47]. This correct charging of one of the 
20 proteinogenic amino acids enables efficient and accurate translation of the genetic 
code. aaRS can be divided into two subclasses, whereby composition of the catalytic 
domain is defining. It is well studied that class I aaRS which contain a catalytic domain 
with Rossmann fold are predominantly selecting for hydrophobic amino acids and their 
corresponding tRNAs. The catalytical core structure of class II tRNA synthetases 
possesses three β hairpins with a large loop between β-strands 2 and 3 which includes 
the characteristic Motif II [48]. Here, the uniqueness of lysyl-tRNA synthetase (LysRS) 
Introduction 
9 
 
becomes perceptible as class I and class II LysRS both exist and are unrelated to each 
other [49]. The first-mentioned variant is present in Euryarchaeota, Spirochaetes and 
Rickettsia whereas the last-named is found in eukaryotes, the rest of bacteria and the 
crenarchaea [49]. For class IIb aaRSs (including aaRS for lysine, aspartate and 
asparagine), Smith et al. suggest that their evolutionary origin lays in a single tRNA 
synthetase putatively able to recognize an ancient precursor of lysine, an early 
available and positively charged compound like 2,4-diamino butyric acid or 2,3-diamino 
propionic acid [48]. 
However, lysyl-tRNA synthetase class II not only covers LysRS but also the interesting 
enzyme EpmA [50] that has evolved an entirely new function in a large subset of 
bacteria. In 1991, EpmA was first described as “new protein resembling a lysyl-tRNA 
synthetase”. Indeed, EpmA shows 31 % amino acid identity with the C-terminal domain 
of LysRS from E. coli but lacks the N-terminal OB-fold anticodon binding domain [19, 
50]. In parallel to aaRSs, two successive reactions are catalyzed by a single enzyme 
(Figure 5). First, the carboxyl group of an amino acid is activated in an ATP-dependent 
condensation reaction to form enzyme-bound aminoacyl adenylate (aa-AMP). Specific 
binding of the correct amino acid is ensured by EpmA’s catalytic pocket amino acid 
composition, in particular side chain size, charges and hydrogen bonding potential [48]. 
The second step includes ligation with the acceptor and concurrent AMP release from 
the catalytic pocket. EF-P as the acceptor molecule admittedly resembles tRNA 
structure by shape, but remarkably is a protein instead of a RNA molecule [22]. In the 
case of EpmA the activated amino acid (R)-β-lysine is transferred to K34 at the loop of 
EF-P. As paralog of LysRS, EpmA lost its function to acylate tRNALys but has evolved 
the ability to ligate EF-P and (R)-β-lysine [51].  
Even before the function of EpmA as PTM enzyme of EF-P was solved, Ambrogelly et 
al. demonstrated EpmA’s promiscuity towards its donor substrate [51]. Enzyme 
promiscuity is characterized by accidental binding of a non-canonical substrate to the 
active site and subsequent turn-over. The promiscuous ability provides a fitness 
advantage during environmental changes and can finally result in new enzymes when 
gene duplication is followed by divergence [52].  
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Figure 5: Similarity of LysRS charging tRNALys and EpmA charging EF-P. Depicted is the 
parallelism of protein structures and shapes as well as enzyme mechanisms between 
aminoacylation of tRNALys catalyzed by lysyl-tRNA synthetase (LysRS, upper part) and PTM of 
EF-P by modification enzyme EpmA (lower part). LysRS and EpmA belong to lysyl-tRNA 
synthetase class II but at the latter, the anticodon binding domain is missing.  Both reaction 
mechanisms contain the substep of donor substrate activation to form aminoacyl adenylate (aa-
AMP) bound to the enzyme and the subsequent transfer of the activated amino acid to the 
acceptor substrate. 
It is known that the specific recognition of the amino acid by a tRNA synthetase as well 
as by EpmA is error prone [51, 53]. For example, tRNALys is mischarged by LysRS with 
non-cognate substrates like arginine, threonine, methionine, leucine, alanine, serine 
and cysteine in vitro [54]. Moreover, Ambrogelly et al. were able to demonstrate 
substrate promiscuity of EpmA due to activation of 5-hydroxy-L-lysine, (S)-α–lysine (L-
lysine), diaminopimelic acid (DAP) and thialysine ((S)-(2-aminoethyl)-L-cysteine) [51]. 
Misactivated aa-AMP can be cleaved by the enzyme. In the case of aaRS this 
distinction between cognate and non-cognate aa-AMP is known as pre-transfer editing 
[55, 56]. Notably, it is reported that pre-transfer editing is also observed in absence of 
Introduction 
11 
 
the tRNA as acceptor, allowing the two partial reactions to be studied individually [57, 
58].  
1.6 Aim of the study 
Having demonstrated the importance of EF-P for proper translation of proteins 
containing ribosome stalling motifs and having introduced the dependence on the 
central PTM enzyme EpmA, the question arises how EF-P and EpmA interplay in 
E. coli to finally ensure EF-P functionality in vivo. This lays the foundation and 
motivation for the research of this thesis. Are the protein copy numbers coordinated to 
ensure complete modification of EF-P during all growth phases? Which chemical 
prerequisites need to be fulfilled to serve as EpmA substrate leading to successful 
binding, activation and finally transfer to K34 of EF-P? Is it possible to use the 
knowledge on interplay of EF-P and EpmA to artificially modify EF-P to create novel 
post-translationally modified variants of EF-P? These research questions are tackeled 
in the following chapters, including development and application of EF-P modification 
detection techniques.  
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2 Material and methods 
2.1 General 
2.1.1 Strains, primers and plasmids  
All strains, primers and plasmids used in this study are listed in Table 1, Table 2 and 
Table 3. 
Table 1: Bacterial strains used in this study. 
Strain Feature Reference 
B. subtilis 168 trpC2 [59]  
AG 
Bramkamp 
B. subtilis ΔalaT BKE31400, yugH trpC2 ΔyugH::erm BGSC 
B. subtilis Δdat BKE09670, trpC2 Δdat::erm BGSC 
B. subtilis Δefp trpC2 Δefp Jörg Stülke 
B. subtilis ΔepsN BKE34230, trpC2 ΔepsN::erm BGSC 
B. subtilis Δfrl BKE32610, trpC2 ΔfrlB::erm BGSC 
B. subtilis ΔgsaB BKE08710, trpC2 ΔgsaB::erm BGSC 
B. subtilis ΔilvE BKE02390, ybgE trpC2 ΔilvE::erm  BGSC 
B. subtilis ΔkbI BKE17000, trpC2 ΔkbI::erm BGSC 
B. subtilis ΔmtnE BKE13580, trpC2 ΔmtnE::erm BGSC 
B. subtilis ΔserC BKE10020, trpC2 ΔserC::erm BGSC 
B. subtilis ΔspsC BKE37890, trpC2 ΔspsC::erm BGSC 
B. subtilis ΔyaaO BKE00270, trpC2 ΔyaaO::erm BGSC 
B. subtilis ΔyhdR BKE09570, trpC2 ΔyhdR::erm BGSC 
B. subtilis ΔyhxA BKE09260, trpC2 ΔyhxA::erm BGSC 
E. coli BL21 (DE3) E. coli B F- dcm ompT hsdS (rB- mB-) gal [60] 
E. coli BW25113 Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), 
λ-, rph-1, Δ(rhaD-rhaB)568, hsdR514 
[61] 
E. coli BW25113 Δefp JW4106, BW25113 efp::npt, KanR [61] 
E. coli BW25113 ΔepmA Resistance free mutant of JW4116 [61], 
KanS 
[38] 
E. coli BW25113 ΔepmB 
CmR 
SU1, BW25113 yjeK643-1029::cat, 
CmR 
[16] 
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E. coli BW25113 ΔepmB 
CmS 
Resistance free mutant of SU1 [16], 
exclusively this E. coli ΔepmB strain 
was used for experiments, CmS 
This study 
E. coli BW25113 ΔepmC Resistance free mutant of JW5381 [61], 
KanS 
Lassak 
unpublished 
E. coli DH5αpir endA1 hsdR17 glnV44 (= supE44) thi-1 
recA1 gyrA96 relA1 
φ80dlacΔ(lacZ)M15 Δ(lacZYA-
argF)U169 zdg-232::Tn10 uidA::pir+ 
[62]  
E. coli LF1 Plac efp Additional efp copy at Plac in LF 1 (F- λ- 
ilvG rfb50 rph1 rpsL150   Plac::rps-neo-
kan::lacZ#) background 
Volkwein 
unpublished 
E. coli LMG194 F- ΔlacX74 galE galK thi rpsL ΔphoA 
Δara714 leu::Tn10 
[63]  
E. coli MG1655 F- λ- ilvG rfb50 rph-1 [64] 
E. coli MG1655 ΔepmB TK1, MG1655 yjeK643-1029::npt, KanR [16] 
M. luteus  DSM 20030 
S. griseus  DSM 40236 
S. oneidensis MR-1  [65] 
S. oneidensis Δefp Δ2328 [37] 
S. venezuelae  
ATCC 10712 
 DSM 40230 
 
Table 2: Oligonucleotides. All primers were purchased from Sigma-Aldrich and diluted to 10 μM 
stock solutions.  
 
Oligonucleotide 
name 
Primer sequence (5’ - 3’) 
Restriction 
site 
P1 
XbaI_SUMO_efp
Bs_fw 
TCC TCT AGA AAT AAT TTT GTT T XbaI 
P2 
XbaI_SUMO_efp
Bs_rv 
AAC TGA AAT CAT ACC ACC AAT 
CTG 
 
P3 HindIII_efpBs_fw 
CAG ATT GGT GGT ATG ATT TCA 
GTT 
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P4 HindIII_efpBs_rv AGC CAA GCT TCT ATG CTC TTG A HindIII 
P5 
XbaI_SUMO_efp
So_fw 
TCC TCT AGA AAT AAT TTT GT XbaI 
P6 
XbaI_SUMO_efp
So_rv 
AGC AGT TTT CAT ACC ACC AAT 
CTG 
 
P7 HindIII_efpSo_fw 
CAG ATT GGT GGT ATG AAA ACT 
GCT 
 
P8 HindIII_efpSo_rv AGC CAA GCT TTT AAA CGC GCT T HindIII 
P9 
SacI_sRBS_His6
_epmA_fw 
ATC GAG CTC AGC GTA AGC CGA 
GAG AAC TAA GGA GGT CTA AAA 
TGC ATC ACC ATC ACC ATC ACG 
GCA GCA GCG AAA CGG CAT CCT 
GGC A 
SacI 
P10 XbaI_epmA_rv 
GAC TCT AGA TTA TGC CCG GTC 
AAC GCT AAA GGC 
XbaI 
P11 pBAD33_seq_fw GGC GTC ACA CTT TGC TAT GC  
P12 epmA_A294G_rv 
CGA TCA ACA CCT AAA CCC ACG 
CCG GAA CAG TCA 
 
P13 epmA_A294G_fw 
TGA CTG TTC CGG CGT GGG TTT 
AGG TGT TGA TCG 
 
P14 pBAD-HisA-rev CAG TTC CCT ACT CTC GCA TG  
P15 R303I_rv 
CGC CAA CAT CAC CAG AAT ATC 
AAC ACC TAA TGC 
 
P16 R303I_fw 
GCA TTA GGT GTT GAT ATT CTG 
GTG ATG TTG GCG 
 
P17 R303L_rv 
CGC CAA CAT CAC CAG AAG ATC 
AAC ACC TAA TGC 
 
P18 R303L_fw 
GCA TTA GGT GTT GAT CTT CTG 
GTG ATG TTG GCG 
 
P19 R303S_rv 
CGC CAA CAT CAC CAG ACT ATC 
AAC ACC TAA TGC 
 
P20 R303S_fw 
GCA TTA GGT GTT GAT AGT CTG 
GTG ATG TTG GCG 
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Check Primer   
 epmA_inside_rv TTC ATT ACG GAA GCT GCG GCA This study 
 
epmA_seq_fw  
(yjeA-fw-seq) 
GCC CTT GTC AAA AAC TGG AG S. Ude 
 
epmA_seq_rv  
(yjeA-rev-seq) 
CTG AAA AAT TAC TGA ATT AAC 
AGC G 
S. Ude 
 epmB_inside_rv GAT CAC AAT CGG CAG ACG GCT This study 
 epmB_seq_fw 
GCA CGA TGT AGG CCT GAT AAG 
CG 
This study 
 epmB_seq_rv AGA CCA GCA CGA AAA TCG TTG CT This study 
 
epmB_up50 
(up50_yjeK) 
CGT TGC CAT AAG GCC CTC TGA 
AAT TTG TTA ATT GGT AGC TAA 
GCC ACA AAA ATT AAC CCT 
T. 
Kraxenberger 
 
epmB_down50 
(down50_yjek) 
AAG CGT AGC GAA TCA GGC AAT 
TTT AAT GTT TAA CTT CCC TGT TTA 
ATC AGT AAT ACG ACT 
T. 
Kraxenberger 
 T7_prom TAA TAC GAC TCA CTA TAG GG S. Ude 
 E. coli EF-P fw 
GGC CTC GAG ATG GCA ACG TAC 
TAT AGC AAC GAT TTT C 
This study 
 E. coli EF-P rv 
AAG ATC GGA TCC TTA GTG ATG 
GTG ATG GTG ATG CTT CAC GCG 
AGA GAC GTA TTC ACC AGA 
This study 
 pET16b_chk_fw AAC AAA TAG GGG TTC CGC This study 
 
Table 3: Plasmids used in this study. 
Plasmid name Feature Reference 
p3LC-TL30-3P-CCG 
Equivalent to pBBR1_MCS3_TL30_ 
3*CCG_lacZ, TL30 fragment of cadC fused 
to 3 x CCG (coding for a triproline motif) and 
lacZ, TetR 
[16] 
pACycDuet_AcKRST 
Contains the gene for acetyllysyl-tRNA-
synthetase (AcKRS), a variant of 
[66] 
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pyrrolysyl-tRNA-synthetase (PylRS) from 
Methanosarcina mazei, CmR 
pBAD/HisA_GIWPPP_
nptI 
Triproline motif cloned upstream of 
neomycin phosphotransferase I 
(kanamycin resistance cassette), 
arabinose-inducible pBAD/HisA, AmpR, 
KanR 
Volkwein 
unpublished 
pBAD24_sRBS_efpEco
K34TAG_His6 
C-terminally His6-tagged E. coli efp 
containing the amber codon TAG at 
position K34, synthetic ribosome binding 
site, arabinose-inducible pBAD24, AmpR 
[67] 
pBAD24-efpEco K34R 
C-terminally His6-tagged E. coli efp, coding 
for the amino acid substitution variant EF-
P_K34R, arabinose-inducible pBAD24, 
AmpR 
[38] 
pBAD24_His10_epmB 
N-terminally His10-tagged E. coli epmB, 
arabinose-inducible pBAD24, AmpR 
[68] 
pBAD33 
Expression vector with pACYC184/p15A 
origin of replication, arabinose-inducible 
PBAD, CmR 
[63] 
pBAD33_epmA 
E. coli epmA, arabinose-inducible pBAD33, 
CmR 
[38] 
pBAD33_His6_efp 
N-terminally His6-tagged E. coli efp, 
arabinose-inducible pBAD33, for production 
of unmodified EF-P in E. coli ΔepmA, CmR 
[37] 
pBAD33_His6_efp_ 
epmAB 
N-terminally His6-tagged E. coli efp, epmA 
and epmB, arabinose-inducible pBAD33, 
for production of post-translationally 
modified EF-P, CmR 
[38] 
pBAD33_His10_epmB 
N-terminally His10-tagged E. coli epmB, 
arabinose-inducible pBAD33, CmR 
This study 
pBAD33_sRBS_His6_ 
epmA 
N-terminally His6-tagged E. coli epmA, 
arabinose-inducible pBAD33, synthetic 
ribosome binding site, CmR 
[67] 
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pBAD33_sRBS_His6_ 
epmA_A298G 
N-terminally His6-tagged E. coli epmA, 
coding for the amino acid substitution 
variant EpmA_A298G, arabinose-inducible 
pBAD33, synthetic ribosome binding site, 
CmR 
[67] 
pBAD33_sRBS_His6_ 
epmA_R303I 
N-terminally His6-tagged E. coli epmA, 
coding for the amino acid substitution 
variant EpmA_R303I, arabinose-inducible 
pBAD33, synthetic ribosome binding site, 
CmR 
This study 
pBAD33_sRBS_His6_ 
epmA_R303L 
N-terminally His6-tagged E. coli epmA, 
coding for the amino acid substitution 
variant EpmA_R303L, arabinose-inducible 
pBAD33, synthetic ribosome binding site, 
CmR 
This study 
pBAD33_sRBS_His6_ 
epmA_R303S 
N-terminally His6-tagged E. coli epmA, 
coding for the amino acid substitution 
variant EpmA_R303S, arabinose-inducible 
pBAD33, synthetic ribosome binding site, 
CmR 
This study 
pBAD33_SUMO_efpE.c. 
N-terminally His6-SUMO-tagged E. coli efp, 
arabinose-inducible pBAD33, CmR 
This study 
pBAD33_SUMO_efpB.s. 
N-terminally His6-SUMO-tagged B. subtilis 
efp, arabinose-inducible pBAD33, CmR 
This study 
pET 
Expression vector with pBR322 origin of 
replication, IPTG-inducible PT7, KanR  
[69] 
pET_SUMO-efpEco 
C-terminally His6-SUMO-tagged E. coli efp, 
IPTG-inducible pET, KanR 
[38] 
pET_SUMO-efpEco 
K34R 
C-terminally His6-SUMO-tagged E. coli efp, 
coding for the amino acid substitution 
variant EF-P_K34R, IPTG-inducible pET, 
KanR 
[38] 
pET_SUMO-efpEco 
P32S 
C-terminally His6-SUMO-tagged E. coli efp, 
coding for the amino acid substitution 
[38] 
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variant EF-P_P32S, IPTG-inducible pET, 
KanR 
pET_SUMO_efpS.o. 
N-terminally His6-SUMO-tagged 
S. oneidensis efp, IPTG-inducible pET, 
KanR 
This study 
pET16b_RPAP_nluc 
Nonstalling motif RPAP cloned upstream of 
nluc, IPTG-inducible pET16b, AmpR 
Pinheiro 
unpublished 
pET16b_RPPP_nluc 
Arginine-triproline motif cloned upstream of 
nluc, IPTG-inducible pET16b, AmpR 
[67] 
pET16b_SUMO_efpE.c. 
N-terminally His6-SUMO-tagged E. coli efp, 
IPTG-inducible pET16b, AmpR 
This study 
pRED/ET AmpR 
λ-RED recombinase, arabinose-inducible 
pBAD24, AmpR 
Gene 
Bridges 
 
2.1.2 Standard chemicals and cultivation of bacteria  
Acetic acid, acetone, ammonium peroxodisulfate (APS), L(+)-arabinose, L-arginine 
hydrochloride, CHAPS, 1,4-dithiothreitol (DTT), ethylenediaminetetraacetic acid 
(Na2EDTA), ethanol (EtOH), 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid 
(HEPES), glycerol, glycine, (S)-α-lysine hydrochloride, methanol (MeOH), MgCl2, 
piperazine-N,N’bis(2-ethanesulfonic acid) (PIPES), SDS, sodium bicarbonate 
(NaHCO3), D(+)-sucrose, TCA, tetramethylethylenediamine (TEMED) and 
tris(hydroxymethyl)-aminomethane (Tris) were purchased from Roth. Adenosine 5’-
triphosphate disodium salt (ATP), (R)-3-aminohexanoic acid hydrochloride, (S)-3-
aminohexanoic acid hydrochloride, 6-AC, bromophenol blue (BPP), 
deoxyribonuclease I from bovine pancreas (DNase), 2,6-diaminopimelic acid (DAP), 
KCl, lysozyme, phenylmethylsulfonyl fluoride (PMSF), (S)-α-ornithine hydrochloride, 
TCE and urea were purchased from Sigma-Aldrich. (RS)-5-hydroxy-(S)-α-lysine, (R)-
α-lysine hydrochloride and thiourea were provided by Fluka. Isopropyl-β-D-
thiogalactopyranoside (IPTG) and NaCl was purchased from PanReac AppliChem and 
L-glutamine from Serva.  
(3R)-3,5-diaminopentanoic acid dihydrochloride ((R)-β-ornithine) was provided by 
AKos GmbH. (R)-β-lysine was synthesized by Carbolution Chemicals, (S)-β-lysine was 
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purchased from PepTech Corporation. All lysine derivatives were dissolved in ddH2O 
(SG Ultra Clear UV plus Watersystem). 
TEA buffer: 20 mM triethanolamine hydrochloride (Sigma), pH 7.5  
HEPES buffer: 50 mM HEPES, 100 mM NaCl, 50 mM KCl, 10 mM MgCl2, 5 v% 
glycerol, pH 7.0  
M. luteus, S. griseus, and S. venezuelae were cultivated at 30 °C in LB medium (10 g/L 
NaCl, 10 g/L tryptone/peptone ex casein (Roth), 5 g/L Bacto Yeast Extract (BD), pH 
7.0) supplemented with 0.5 v% glycine. S. oneidensis was grown at 30 °C in LB 
medium. B. subtilis and E. coli were cultivated at 37 °C using LB medium. When 
necessary the medium was solidified using 30 mg/mL Difco agar (BD) and 
supplemented with antibiotics in the following concentrations: 100 μg/mL ampicillin 
sodium salt (Roth), 100 μg/mL carbenicillin disodium salt (Roth), 50 μg/mL kanamycin 
sulphate (Roth), 34 μg/mL chloramphenicol (Roth), or 12.5 μg/mL tetracycline 
hydrochloride (Sigma).  
Optical density at 600 nm wavelength (OD600) of cultures were measured using 
Ultrospec 2100 pro (Amersham Biosciences). The growth curve of BW25113 ΔepmB 
transformed with the plasmids pBAD33 and p3LC-TL30-3P-CCG was recorded using 
Spark 20M multimode microplate reader (Tecan) at 37 °C. Here, the LB medium was 
supplemented with varying amounts of (R)-3-AC (0.02 to 10 mM) and OD600 was 
measured every 15 min for 14 h.  
2.1.3 Molecular genetic methods and Miscellaneous 
Plasmids were reproduced by transformation of E. coli DH5α and subsequent plasmid 
isolation procedure using the Hi Yield Plasmid Mini Kit (Süd-Laborbedarf). Genomic 
DNA was extracted using UltraClean Microbial DNA Isolation Kit (MO BIO 
Laboratories) according to instructions. Samples were stored at -20 °C. 
Standard DNA techniques like restriction (different enzymes, NEB), ligation (T4 DNA 
ligase, NEB) and PCR (OneTaq Polymerase, Q5 High-Fidelity DNA Polymerase, both 
NEB) were performed according to manufacturer’s instructions. DNA fragments were 
separated in 10 mg/mL agarose (Serva) electrophoresis gel supplemented with Midori 
Green Advance Stain (NIPPON Genetics Europe) which was placed in a Bio-Rad 
Horizontal DNA gel electrophoresis chamber for 20 min at 120 V and using TAE buffer 
(20 mM acetic acid, 1 mM EDTA, 40 mM Tris, pH 8) as running buffer. Prior to loading 
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samples were mixed with 6X DNA loading dye (0.3 mg/mL BPP, 0.3 mg/mL xylene 
cyanol FF (Serva), 60 v% glycerol, 10 mg/mL SDS, 10 mM EDTA). 2-Log DNA Ladder 
(0.1 - 10.0 kb) was purchased from NEB. Gel Doc EZ Gel Documentation System (Bio-
Rad) was used to save agarose gel pictures. Subsequent DNA extraction was 
conducted using Hi Yield PCR Clean-Up & Gel-Extraction Kit (Süd-Laborbedarf). DNA 
as well as protein concentrations were measured using NanoDrop ND-1000 
(NanoDrop Technologies).  
Chemically competent E. coli cells were obtained by inoculation (1:100) of 200 mL LB 
medium with ON culture. When the culture has grown to OD600 = 0.3 – 0.6 it was placed 
on ice for 10 min. After centrifugation for 10 min at 4 °C at 5,000 rpm (Eppendorf 
5415R, rotor FA-45-24-11) the pellet was resuspended in 100 mL transformation buffer 
(50 mM CaCl2 · 2 H2O (Baker), 15 v% glycerol, 10 mM PIPES, pH 6.6) and stored on 
ice for 20 min. After repeated centrifugation, the pellet was resuspended in 10 mL 
transformation buffer, split in 250 μL aliquots and stored at -80 °C. 
For transformation 1 - 5 μL of plasmid were mixed with 250 μL chemically competent 
E. coli cells. After 30 min storage on ice a heat shock was conducted at 42 °C for 
90 sec. 1 mL LB medium was added and agitated for 1 h at 37 °C. A part of the culture 
was finally exposed to a LB agar plate supplemented with the corresponding antibiotic 
for selective colony growth at 37 °C ON.  
Newly designed plasmids and strains were subjected to colony PCR using OneTaq 
polymerase according to manufacturer’s instructions and sequenced by LMU 
Sequencing Service. Samples were processed on ABI 3730 capillary sequencers with 
50 cm capillary length. 
PDB entries of crystal structures shown in this work are the following:  
EF-P of P. aeruginosa in Figure 7: 3OYY 
EpmA (GenX, YjeA) of E. coli in complex with EF-P in Figure 2, Figure 4, Figure 18C, 
Figure 19, Figure 21: 3A5Z 
EpmC (YfcM) of E. coli in Figure 4: 4PDN 
LysRS of E. coli in Figure 5: BBU 
tRNAAsp of E. coli in Figure 5: 1EFW 
Theoretical pI values were calculated using ExPASy pI/Mw tool [70]. 
Material and methods 
21 
 
The Phyre2 web portal for protein modeling, prediction and analysis [71] was used to 
analyze secondary structure elements of EF-P and to predict structure of EpmB (YjeK) 
of E. coli in Figure 4. 
Molecular graphics and analyses were performed with UCSF Chimera, developed by 
the Resource for Biocomputing, Visualization, and Informatics at the University of 
California, San Francisco, with support from NIH P41-GM103311 [72]. 
Chemical structures were designed using ChemDraw Professional (version 16.0.0.82, 
PerkinElmer Informatics). 
When necessary, grey density analysis was performed using ImageJ [73]. 
Sequencing results, amino acid alignments and primer design was conducted using 
CLC Genomics Workbench 7.7 (https://www.qiagenbioinformatics.com/). 
Graphs, Km calculations and two-tailed t-tests were created and performed using 
GraphPad Prism version 5.03 for Windows, GraphPad Software, La Jolla California 
USA, www.graphpad.com. 
2.2 Peptide antibody generation 
Peptides NH2-C+TEPGVKGDTAGGTKP-CONH2 and NH2-C+VPLFINEGEKIKVDT-
CONH2 were selected for the Eurogentec Anti-Peptide Polyclonal Antibody program 
AS-SUPR-DXP (AS-SUPR-DX + 2 x 5 mL purify). The two peptides were synthesized 
and conjugated to the carrier keyhole limpet hemocyanin (KLH). Each of two rabbits 
was immunized with two peptides. After 28 days that included four injections and three 
bleeds, blood was harvested, and serum collected. ELISA test determined and 
compared the titer in preimmune serum and large bleed serum. Affinity purification with 
the synthesized peptides removed unspecific antibodies and yielded polyclonal peptide 
antibodies P68 and P69, respectively.  
2.3 Preparation of bacterial lysates  
If not otherwise mentioned, strains were grown ON and harvested the next day. OD600 
was set using TEA or HEPES buffer. DNase was added and incubated 30 min at RT. 
For Gram-positive bacteria, 1 mg/mL lysozyme was included at this incubation step. 
Small volumes (< 10 mL) were lysed using BRANSON Digital Sonifier (30 % 
amplitude, 0.5 sec pulse, 0.5 sec pause for 2 x 30 sec) under constant ice-cooling. 
Larger volumes were lysed using a cell disruptor (Constant Systems Ltd, iX T4A, 3 x 
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at 1.35 kbar). After 20 min of centrifugation at 4 °C and 5,000 rpm (Eppendorf 
Centrifuge 5804 R, rotor A-4-44), the clear supernatant was used for further analysis.  
For characterization of antibodies P68/P69 OD600 of E. coli BW25113, B. subtilis and 
S. oneidensis (WT and Δefp each) was set to 50 using TEA buffer. Additionally, 0.5 mM 
PMSF was added. E. coli and S. oneidensis cells were lysed by vortexing with 
MicroBeads (from UltraClean Microbial DNA Isolation Kit, MO BIO Laboratories) for 
10 min. MicroBeads were spinned down and the supernatant was mixed with 5X SDS 
loading dye, heated for 10 min to 95 °C and centrifuged for 10 min.    
2.4 Cloning strategies for plasmid and strain constructions 
2.4.1 His6-SUMO-tagged efps from different organisms  
His6-SUMO was fused to the N-terminus of efp and subsequently following plasmids 
were constructed: pBAD33_SUMO_efpE.c., pET16b_SUMO_efpE.c., 
pBAD33_SUMO_efpB.s. and pET_SUMO_efpS.o.. Cleavage by SUMO protease Ulp 
allowed for production of the native protein. 
For the first-mentioned plasmids, pET_SUMO_efpEco was digested using XbaI and 
HindIII as restriction sites. The resulting fragment was subsequently ligated to pBAD33 
and pET16b backbone, respectively. For pBAD33_SUMO_efpB.s. construction, the 
His6-SUMO fragment was amplified from pBAD33_SUMO_efpE.c. using the primer pair 
P1/P2. Genomic DNA of B. subtilis 168 served as template for amplification of efp 
using primers P3/P4. Overlap extension PCR led to a fragment that was subsequently 
digested using restriction enzymes XbaI and HindIII. These restriction sites were used 
to insert His6-SUMO-efpB.s. into plasmid backbone pBAD33. Accordingly, 
pET_SUMO_efpS.o. was constructed following a similar procedure for S. oneidensis 
MR-1 using primers P5 – P8 and plasmid backbone pET.  
2.4.2 His6-tagged EpmA and its variants A298G, R303I/L/S and His10-
tagged EpmB 
pBAD33_epmA was used as template for construction of pBAD33_sRBS_His6_epmA 
using P9/P10. The synthetic ribosome binding site was calculated using RBS 
Calculator (https://salislab.net/software/, De Novo DNA). SacI and XbaI restriction sites 
were used for digest of fragment and backbone. It must be noted that the His6-tag was 
also introduced C-terminally but this variant was non-functional (not shown). 
Subsequently, amino acid exchange A298G was introduced by overlap PCR using 
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P11 – P14. Amino acid substitutions of R303 were conducted by overlap PCR using 
pBAD33_sRBS_His6_epmA as template and primer pair P11/P15 P16/P14 for R303I, 
P11/P17 P18/P14 for R303L and P11/P19 P20/P14 for R303S. The fragments were 
digested using SacI and XbaI and ligated to pBAD33. 
His10-tagged epmB fragment was amplified from pBAD24_His10_epmB using P11/P14 
and digested at restriction sites NsiI and XbaI. The resulting fragment was ligated to 
pBAD33 to yield pBAD33_His10_epmB. 
2.4.3 Removal of resistance cassette to create antibiotic-sensitive strains 
The selection marker of BW25113 ΔepmB CmR (SU1) was removed by FLP/FLPe 
expression from pRED/ET AmpR. Quick & Easy E. coli Gene Deletion Kit (Gene 
Bridges) was used according to the manufacturer’s instructions to create BW25113 
ΔepmB CmS. This strain was used throughout the whole study. 
2.5 Overexpression and purification of EF-Ps from E. coli, B. subtilis and 
S. oneidensis 
For production of untagged EF-Ps of E. coli, B. subtilis and S. oneidensis, inducible 
plasmids pBAD33_SUMO_efpE.c., pET_SUMO-efpEco K34R/P32S, pBAD33_SUMO_ 
efpB.s. and pET_SUMO_efpS.o. were used, respectively. BW25113 (for modified 
EF-PE.c.), BW25113 ΔepmA (for unmodified EF-PE.c. and EF-PB.s.) and BL21 (for all 
pET vectors) were transformed with one of these plasmids and grown to exponential 
growth phase. Gene expression was induced by addition of 2 g/L arabinose (for pBAD) 
or 1 mM IPTG (for pET). After 5 h, cultures were harvested by centrifugation (20 min, 
4 °C, 5,000 rpm, Beckman Coulter Avanti JXN-26, rotor JLA-8.1000). The pellet was 
resuspended in TEA buffer to yield a concentration of 0.2 g/mL. After addition of 10 mg 
DNase incubated at RT for 30 min, cells were lysed using a cell disruptor (Constant 
Systems Ltd, iX T4A, 3 x at 1.35 kbar). Ultracentrifugation was conducted for 1 h at 
45,000 rpm (Beckman Coulter Optima L-90K, Rotor 50.2 Ti). His6-SUMO-tagged EF-P 
was purified using Ni-NTA agarose (nitrilotriacetic acid, Qiagen) according to the 
following quick protocol. 1 mL beads were washed and resuspended one time with 
ddH2O and two times with TEA buffer. After each round, centrifugation at 4 °C for 3 min 
at 2,000 rpm (Eppendorf Centrifuge 5804 R, rotor A-4-44) was conducted. The 
equilibrated beads were incubated with the supernatant from the ultracentrifugation 
step for 1 h at 4 °C. The IMAC column (immobilized metal ion affinity chromatography 
FLEX-COLUMNS, Thermo Fisher) was washed with ddH2O (1 x) and with TEA buffer 
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(2 x). The bead suspension was added to the column and subsequently, flow-through 
was collected for SDS-PAGE analysis. Washing steps were performed twice using 
10 mL of TEA buffer + 20 mM imidazole (Roth) and the final elution was conducted 
using 400 mM imidazole. Samples were dialyzed (SERVAPOR dialysis tubing MWCO 
12,000 – 14,000, Serva, cooked in 20 g/L NaHCO3 + 0.37 g/L EDTA and stored in 
1 mM EDTA) two times for 4 h to remove imidazole. 15 wt% (compared to total protein 
mass) of SUMO protease (Ulp, Invitrogen, [74, 75]) was added and incubated for 5 h 
at 30 °C. After incubation with fresh and equilibrated Ni-NTA agarose beads for 1 h, 
chromatography flow-through was collected to yield untagged EF-P. Successful 
purification of the target protein was ensured by SDS-PAGE, visualized by TCE 
staining (Chapter 2.6.1) and when necessary by vertical IEF (Chapter 2.6.5).  
For overexpression and purification of His6-tagged EF-P of E. coli in different 
modification states, His6_efp was overexpressed from pBAD33_His6_efp in BW25113 
ΔepmA (unmodified EF-P), from pBAD33_efp_epmAB in BW25113 (modified EF-P) or 
from pBAD33_His6_efp in BW25113 ΔepmC (unhydroxylated EF-P).  
For production of EF-P with acetyllysine at position 34, C-terminally His6-tagged efp 
was overexpressed from pBAD24_sRBS_efp(Eco)K34TAG_His6 in E. coli LMG194. 
Moreover, the strain was transformed with pACycDuet_AcKRST to allowed for amber 
suppression with the acetyllysine-tRNA synthetase (AcKRS) described by Volkwein et 
al. [66]. LB medium was supplemented with 5 mM Nε-acetyl-L-lysine (Sigma-Aldrich) 
and 1 mM nicotinamide (Sigma-Aldrich) to prevent deacetylation by CobB [76]. 
Amino acid exchange variant K34R was overexpressed from pBAD24-efpEco K34R in 
BW25113 ΔepmA (modification prevented) or WT. Here, additional epmA 
overexpression was conducted using pBAD33_sRBS_His6_epmA (modification 
stimulated). The above-mentioned procedure was varied by using HEPES buffer 
instead of TEA buffer for pellet resuspension and purification. Moreover, Ulp digest 
and the following second purification step was omitted.  
Parallel overexpressions of His6_efp_K34R and His6_epmA require an additional 
separation step due to the similar protein tags. Therefore, EpmA and EF-P were 
separated by Size Exclusion Chromatography performed at ÄKTA pure 
chromatography system (GE) equipped with a Superdex 200 Increase 10/300 GL 
column (GE). The fraction containing EF-P but not EpmA was elucidated by SDS-
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PAGE analysis and concentrated using sucrose. To do so, a highly concentrated 
sucrose gel was prepared in a 250 mL flask filled with sucrose up to the 150 mL mark. 
Then, HEPES buffer was added up to the 250 mL mark and the solution was stirred at 
4 °C ON and stored until use. The protein sample was filled in a dialysis tube 
(SERVAPOR dialysis tubing MWCO 12,000 – 14,000, Serva, cooked in 20 g/L 
NaHCO3 + 0.37 g/L EDTA and stored in 1 mM EDTA) and covered with sucrose 
solution. The remaining volume was checked every hour until considerable decrease 
was reached.  
2.6 Electrophoretic methods 
2.6.1 SDS-polyacrylamide gel electrophoresis 
For separation and visualization of proteins, SDS-PAGE was conducted according to 
Lämmli [77]. The stacking gel contained 4.8 v% acrylamide (Roth) and the separating 
gel contained 12.5 v% acrylamide. 0.5 v% TCE was added for protein visualization 
using the Gel Doc EZ Gel Documentation System (Bio-Rad) [78]. Polymerization of the 
gels was induced using APS and TEMED. By default, samples were mixed with 5X 
SDS loading dye (250 mM Tris, 0.1 g/mL SDS, 5 mg/mL BPP, 50 v% glycerol, 500 mM 
DTT, pH 6.8), heated to 95 °C for 10 min and subsequently, 15 to 20 µL were loaded 
per lane. Lonza ProSieve Color Protein Marker (FisherScientific) or Roti-Mark (Roth) 
was used as size standard. Proteins were separated using PerfectBlue SDS-PAGE 
chambers (Peqlab) filled with Lämmli buffer (25 mM Tris, 200 mM glycine, 1 g/L SDS, 
pH 8.2 - 8.3) at 200 V.  
2.6.2 Sample preparation for isoelectric focusing 
To prepare E. coli lysates for native horizontal IEF, cells were grown in 1 L LB medium. 
Samples (at least 5 mL) were taken at different time points. Cells were harvested and 
stored at -20 °C. The pellets were washed (10 mM Tris, 250 mM sucrose, pH 7.0), 
whereby high-salt buffers were avoided in accordance with Westermeier [79]. OD600 
was set to 10 and subsequently, 0.5 mM PMSF was added and incubated for 30 min 
at RT. Cell lysis was conducted using BRANSON Digital Sonifier (30 % amplitude, 
0.5 sec pulse, 0.5 sec pause for 2 x 30 sec) under constant ice-cooling. 20 µL of each 
growth curve sample were subjected to SDS-PAGE. Proteins of each lane were 
visualized using TCE staining and quantified using Image Lab Software 4.1 (Bio-Rad). 
Normalized protein amounts were used for native horizontal IEF gel. 10X loading buffer 
contained 50 v% glycerol and 10 mg/mL BPP.  
Material and methods 
26 
 
To prepare B. subtilis lysates for denaturating horizontal IEF the procedure described 
above was slightly modified. Cell pellets were lysed using 0.5 mM PMSF and 1 mg/mL 
lysozyme. Sonification was conducted 5 x 30 sec and an additional protein 
precipitation step was included. Therefore, 750 µL were mixed with 187.5 µL ice-cold 
50 v% TCA and stored on ice for 15 min. After centrifugation at 2 °C for 15 min at full 
speed the pellet was resolved in 500 µL ice-cold acetone. After 15 min on ice followed 
by centrifugation, remaining acetone was facilitated to evaporate by removal of the cap 
for 30 min. Solubilization was conducted ON using 75 µL of solubilization mix 
according to Westermeier (7 M urea, 2 M thiourea, 40 mg/mL CHAPS, 10 mg/mL DTT, 
0.8 v% carrier ampholyte (Pharmalyte, GE), 20 µg/mL BPP) [79]. 
2.6.3 Native horizontal isoelectric focusing 
The GelPool (GE) was washed with distilled water to make sure it is clean and dust-
free. Rehydration solution (1.1 g D-sorbitol (Roth), 820 µL Pharmalyte pH 4 - 6.5 (GE) 
ad 11 mL) was prepared freshly and pipetted along the long side of the GelPool. The 
precast gel (CleanGel IEF (GE)) was placed with the gel side down into the rehydration 
solution, carefully avoiding bubbles. The gel was rehydrated for 1 h on a rocker, 
whereby the gel was moved during the first 15 min to avoid clogging. Pharmacia 
Biotech Multiphor II was equipped with MultiTemp III Thermostatic Circulator 
(Pharmacia Biotech) to ensure constant cooling to 10 °C and connected to a high 
voltage source (Pharmacia Electrophoresis Power Supply EPS 3500). Gel surface was 
cleaned with a filter paper. 2 mL SERVA Cooling Fluid were pipetted onto the gridline. 
The IEF gel was placed on the cooling platform gel side up and aligned to the gridline 
of the Multiphor II. Platin electrodes were cleaned, dried and placed on the edges of 
the gel. During the prefocusing phase the pH gradient was established (350 V 6 mA 
8 W, 20 min). The gel surface was dried with a filter paper when necessary. Small filter 
papers were placed on the cathode side of the gel and soaked with protein samples. 
The latter were transferred to the gel by applying 250 V for 20 min (4 mA 8 W). Main 
focusing was conducted at 1,000 V (7 mM 14 W) for 4 h, whereby filter papers were 
removed after 2 h. Band sharpening was conducted for 10 min (1250 V 7 mM 18 W). 
A metal wire was placed between gel and plastic sheet which had been placed on a 
1 L Schott bottle (Figure 6). After the gel was carefully removed from its plastic sheet 
it could be subjected to Silver Staining or Western Blotting.  
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Figure 6: Film remover apparatus to separate IEF gel from plastic sheet. Horizontal IEF gels 
require separation from its plastic sheet before Western Blotting can be conducted. The figure 
is adapted from GE Multiphor II manual. 
2.6.4 Denaturating horizontal isoelectric focusing 
Due to the usage of urea for denaturating conditions the protocol described in chapter 
2.6.3 was modified as follows: CleanGel IEF (GE) or Blank FocusGel 24S (Serva) was 
rehydrated for at least 2 h. For the first-mentioned gel the solubilization mix without 
BPP was used. The SERVA gel was rehydrated according to manufacturer’s 
instructions using 12.84 g urea, 4.65 g thiourea, 2.46 mL Pharmalyte 4 - 6.5 (GE), 
1.28 g CHAPS, 0.32 g DTT ad 32 mL. The rehydrated gel could be stored in a plastic 
bag ON. To avoid crystallization of urea the focusing temperature was kept at 15 °C. 
For sample application, small filter paper stripes or a silicone applicator strip were used 
at the cathode side of the gel.  
2.6.5 Vertical isoelectric focusing 
0.5 µg of purified protein was mixed with 2X IEF Sample Buffer (Serva). PerfectBlue 
SDS-PAGE chamber (Peqlab) was filled with SERVA IEF Cathode Buffer 3 - 10 (inner 
tank) and SERVA IEF Anode Buffer (outer tank) and connected to a high voltage 
source (Pharmacia Electrophoresis Power Supply EPS 3500). Wells of the precast 
native vertical IEF gel with a pH gradient range of 4 - 7 (SERVAGel) were rinsed with 
cathode buffer. For clearly distinct bands 5 µL of 2X IEF Sample Buffer without protein 
were loaded in the lanes between two samples. Focusing was conducted at 4 °C for 
1 h at 50 V, 1 h at 200 V and finally bands were sharpened for 40 min at 500 V. The 
gel could be subjected to Coomassie, InstantBlue (Expedeon) or Silver Staining as 
well as Western Blotting. 
2.7 Silver Staining, Western Blotting and antibodies used in this study 
When a staining method with excellent sensitivity was needed, Silver Staining was 
conducted. Therefore, the IEF or SDS-PAGE gel was incubated for at least 1 h in fixing 
solution (50 v% MeOH, 12 v% glacial acetic acid, freshly added 0.05 v% of 37 % 
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formaldehyde (Roth)). Subsequently, the gel was washed with 50 % EtOH (3 x 20 min 
or ON), incubated 1 min in thiosulfate solution (1.25 mM Na2S2O3, Sigma), and washed 
with dH2O (3 x 20 sec). Freshly prepared incubation solution (0.03 mM AgNO3 (Roth), 
0.075 v% of 37 % formaldehyde) was added and incubated for 20 min. After another 
washing step with dH2O (3 x 20 sec), development solution (550 mM Na2CO3 (Roth), 
2 % thiosulfate solution, 0.05 v% of 37 % formaldehyde) was incubated for 3 - 10 min. 
The gel was shortly washed with dH2O and incubated in stop solution (65 mM EDTA) 
for at least 15 min.  
For Western Blotting, proteins were transferred to a nitrocellulose membrane 
(Amersham Protran 0.45 μm NC, GE) prewetted with blot buffer (25 mM Tris, 192 mM 
glycine, 20 v% MeOH) using the Trans-Blot Turbo Transfer System (Bio-Rad). 
Subsequently, the membrane was blocked in buffer A (50 mM Tris, 150 mM NaCl, pH 
7.4) + 30 mg/mL BSA (albumin from bovine serum, Sigma). A suitable primary antibody 
was added and incubated for a defined time. The blot was washed with buffer A (3 x 
5 min) and incubated with Anti-RABBIT IgG (alkaline phosphatase conjugated) as 
secondary antibody (0.1 μg/mL) for 1 h. After washing with buffer A (3 x 10 min), the 
blot was incubated in development solution (50 mM sodium carbonate buffer, pH 9.5, 
1 mg/mL NBT (4-nitro blue tetrazolium chloride, biomol), 10 mg BCIP (5-bromo-4-
chloro-3-indolyl-phosphate, PanReac AppliChem)) until visible color development.  
Table 4: Antibodies used in this study 
Antibody name Feature Supplier 
Anti-EF-P “P68” 
Primary, polyclonal peptide antibody against a 
consensus motif of a wide range of bacterial EF-
Ps, produced in rabbit 
NH2-C+VPLFINEGEKIKVDT-CONH2  
Eurogentec 
Anti-EF-P “P69” 
Primary, polyclonal peptide antibody against a 
consensus motif of a wide range of bacterial EF-
Ps, produced in rabbit 
NH2-C+TEPGVKGDTAGGTKP-CONH2 
Eurogentec 
Anti-EF-PE.c. 
Primary antibody against E. coli EF-P, produced 
in rabbit 
Eurogentec 
Anti-EF-PB.s. 
Primary antibody against B. subtilis EF-P, 
produced in rabbit 
Eurogentec 
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Anti-RABBIT  
Secondary antibody against rabbit, conjugated to 
alkaline phosphatase, produced in goat 
Rockland 
 
2.8 B. subtilis swarming assay 
25 mL of 2X LB were mixed with 6.7 mL of 2X agar and filled to 50 mL for a 0.4 % 
swarming plate. The mixture was poured into a square petri dish (Greiner Bio-One) 
and dried for 5 min in a laminar flow hood. Six colonies were picked, spotted on the 
plate and incubated at 37 °C ON. An image of the plates was recorded, and the 
swarming halos were quantified using Adobe Photoshop Elements 2.0.  
2.9 Experiments with antibiotic gradient plates  
To obtain kanamycin gradient plates, 35 mL of LB agar supplemented with 100 µg/mL 
kanamycin and appropriate other antibiotics was poured into a square petri dish plate 
(Greiner Bio-One) which was placed in a slanted position. 45 mL of LB agar containing 
antibiotics but no kanamycin was poured on the dried, first layer and the plate was 
evenly positioned. 50 µL fresh ON culture of BW25113 ΔepmB transformed with 
pBAD/HisA_GIWPPP_nptI and pBAD33_sRBS_His6_epmA was striked out on the 
whole plate and incubated at 37 °C ON. The five colonies able to grow at highest 
kanamycin concentrations were used to inoculate LB medium. The next day, OD600 
was set to 0.5 and subsequently, 10 µL were striked along the length of a fresh gradient 
plate. Clones that still exhibited a growth advantage on kanamycin were subjected to 
plasmid extraction followed by sequencing of epmA using P11/P14. Moreover, colony 
PCR was used to amplify efp fragment with primer pair E. coli EF-P fw/rv which was 
sequenced to elucidate possible mutations.  
The procedure described above was slightly adjusted to yield gentamicin gradient 
plates. Here, 5 µg/mL gentamicin was added to the first and 2 g/L arabinose to both 
LB agar layers. BW25113 ΔepmB and MG1655 ΔepmB were transformed with 
pBAD33_sRBS_His6_epmA and plated on independent plates. Different EpmA amino 
acid exchange variants were also tested on kanamycin gradient plates. Therefore, 
BW25113 ΔepmB was transformed with pBAD/HisA_GIWPPP_nptI and either 
pBAD33, pBAD33_sRBS_His6_epmA or pBAD33_sRBS_His6_epmA_ 
A298G/R303I/R303L/R303S. 20 µL were striked out alongside the kanamycin plate.  
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2.10 In vitro EF-P modification by EpmA 
For in vitro EF-P modification, 25 μM unmodified His6-tagged EF-P, 2 mM ATP (in 
HEPES buffer, pH 7.0), 5 μM His6-tagged EpmA or its variant EpmA_A298G and 
10 mM lysine derivative were mixed in HEPES buffer and incubated ON at RT. 
Following lysine derivatives were used: 6-AC, (R)- and (S)-3-aminohexanoic acid 
hydrochloride, (S)-arginine hydrochloride, (3R)-3,5-diaminopentanoic acid 
dihydrochloride, 2,6-diaminopimelic acid, (RS)-5-hydroxy-(S)-α-lysine, (S)-glutamine, 
(R)- and (S)-α-lysine hydrochloride, (R)- and (S)-β-lysine, (S)-α-ornithine 
hydrochloride. On the next day, samples were either mixed with 2X IEF buffer (Serva) 
and stored at 4 °C for IEF analysis or stored at -20 °C for intact protein MS conducted 
by collaboration partners (Pavel Kielkowski, TUM). 
For the (R)-β-ornithine/lysine competition assay, the assay described above was 
performed with different concentrations of (R)-β-lysine and (R)-β-ornithine. In vitro 
modified EF-P was analyzed by intact protein MS. 
2.11 [32P]-AMP formation assay 
Hydrolysis of ATP by EpmA in the presence of various amounts of lysine derivative 
was monitored in HEPES buffer for time course experiments and Km determination. 
The instruction published by Chen et al. [80] was adapted as follows. 
For time course experiments 10 or 100 mM 6-AC, 0 or 5 µM unmodified His6-EF-P, 
5 mM DTT, 3 mM [α-32P]-ATP (20 Ci/mol, PerkinElmer) were incubated at 37 °C 
(timepoint 0 min) and the reaction was started by addition of 1 μM His6-EpmA. Aliquots 
were taken at 2, 5, 10, 30 and 60 min and quenched with four volumes of 200 mM 
sodium acetate (Merck, pH 5.0). 1 μL of the mixture was analyzed by thin layer 
chromatography (TLC) in duplicates on PEI cellulose plates (Merck Millipore, pre-
washed with water). The dried plates were developed in a TLC glass chamber using 
0.1 M ammonium acetate (Roth), 5 v% acetic acid. [α-32P]-ATP and [32P]-AMP were 
visualized and quantified by phosphor imaging using Typhoon TRIO Variable Mode 
Imager (Amersham Biosciences) equipped with a red laser (633 nm) and ran with the 
Typhoon Scanner Control v5.0. Acquisition mode was set to “Storage Phosphor” and 
Pixel Size to “100 microns”. Grey densities of the [32P]-AMP (𝐴𝑀𝑃∗) spots were 
compared to the grey density of a known [α-32P]-ATP (𝐴𝑇𝑃∗) amount using ImageJ. 
Equation 1 was used for analysis. The reaction was conducted using 3 mM ATP and 
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20 mM [α-32P]-ATP (Stock solution of Perkin Elmer with 3000 Ci/mmol, 10 mCi/mL, 
3.3 µM). 
Equation 1: Calculation of amount n and concentration c of released AMP during in vitro EpmA 
substrate activation. 
𝑛(𝐴𝑇𝑃∗) = 𝑐(𝐴𝑇𝑃∗)  ∙ 𝑉 = 20 𝑛𝑀 ∙
1.5 µ𝐿
1.5 µ𝐿 + 6 µ𝐿
= 4 𝑓𝑚𝑜𝑙 
𝑛(𝐴𝑀𝑃∗) =
𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦(𝐴𝑀𝑃∗)
𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦(𝐴𝑇𝑃∗)
∙ 4 𝑓𝑚𝑜𝑙 
𝑛(𝐴𝑀𝑃𝑔𝑒𝑠)[𝑛𝑚𝑜𝑙] = 𝑛(𝐴𝑀𝑃
∗)[𝑓𝑚𝑜𝑙] ∙
𝑐(𝐴𝑇𝑃) + 𝑐(𝐴𝑇𝑃∗)
𝑐(𝐴𝑇𝑃∗)
∙ 10−6
= 𝑛(𝐴𝑀𝑃∗)[𝑓𝑚𝑜𝑙] ∙
3 𝑚𝑀 + 20 𝑛𝑀
20 𝑛𝑀
∙ 10−6 
𝑐(𝐴𝑀𝑃𝑔𝑒𝑠𝑎𝑚𝑡)[𝑚𝑀] =
𝑛(𝐴𝑀𝑃𝑔𝑒𝑠)[𝑛𝑚𝑜𝑙] − 𝑛(𝑏𝑙𝑎𝑛𝑘)[𝑛𝑚𝑜𝑙]
𝑉[µ𝐿]
=
[𝑛(𝐴𝑀𝑃𝑔𝑒𝑠) − 𝑛(𝑏𝑙𝑎𝑛𝑘)][𝑛𝑚𝑜𝑙]
0.2 µ𝐿 
 
For Km determination the lysine derivative concentration was varied from 0 to 100 mM 
for high Km substrates and from 0 to 2.5 mM for low Km substrates. Moreover, reaction 
mixtures contained 5 mM DTT, 3 mM [α-32P]-ATP (20 Ci/mol, PerkinElmer) and were 
incubated at 37 °C until initiation with 1 μM EpmA or EpmA_A298G, respectively. After 
15 min the reaction was quenched and processed as described. Km values were 
estimated using nonlinear fitting (least squares (ordinary) fit) of the Michaelis-Menten 
equation that was performed using GraphPad Prism version 5.03 for Windows, 
GraphPad Software, La Jolla California USA, www.graphpad.com. 
2.12 In vitro transcription/translation of RPPP-Nluc 
The PURExpress In Vitro Protein Synthesis Kit (NEB) was used according to 
instructions using pET16b_RPAP_nluc or pET16b_RPPP_nluc and unmodified EF-P, 
in vivo modified EF-P (positive control, EF-PRβlys) or in vitro modified EF-P (Materials 
and methods, Chapter 2.5). For a 12.5 μL reaction mixture 5 μL PURExpress solution 
A, 3.75 μL PURExpress solution B, 0.25 μL RNase inhibitor Murine (NEB), 5 μM EF-P 
and 1 ng pET16b_RPA/PP_nluc was incubated at 37 °C at 300 rpm agitation. At 0, 
2.5, 5, 7.5, 10, 12.5, 15, 20, 25 and 30 min a 1 μL aliquot was quenched with 1 μL 
50 mg/mL kanamycin and stored on ice. Afterwards, 2 μL Nano-Glo Luciferase Assay 
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(Promega) Reagent and 18 μL ddH2O were added to induce luminescence 
development which was detected by the Infinite F500 microplate reader (Tecan). At 
least three independent replicates were analyzed, and significance of the results were 
determined by two-tailed t-test using GraphPad Prism.  
2.13 β-galactosidase activity assay 
BW25113 and deletion mutants BW25113 ΔepmA and BW25113 ΔepmB were 
transformed with the plasmid p3LC-TL30-3P-CCG described by Ude et al. [16]. Here, 
truncated cadC was fused to an EF-P-dependent triproline stalling motif and lacZ. The 
plasmid-encoded complementation of the deletion mutants as well as cross-
complementation was performed using pBAD33_sRBS_His6_EpmA, 
pBAD33_sRBS_His6_EpmA_A298G or pBAD33_His10_epmB, respectively.  
To compare the effects of the different lysine derivatives in vivo, BW25113 ΔepmB was 
transformed with p3LC-TL30-3P-CCG and pBAD33, pBAD33_sRBS_His6_EpmA or 
pBAD33_sRBS_His6_EpmA_A298G. Here, 10 mM lysine derivative was added to the 
medium. (S)-β-lysine was used in the concentration of ~0.25 mM. Concentration of 
(R)-3-AC was reduced to 1 mM due to a growth defect at higher concentrations.  
Co-transformed cells were grown in LB medium ON and harvested by centrifugation. 
Pellets were resuspended in sodium phosphate buffer according to instructions [81]. 
β-galactosidase activities were determined for at least three independent experiments 
and are given in Miller units, which were calculated according to Miller [82].  
2.14 Purification of endogenous EF-P 
BW25113 co-transformed with p3LC-TL30-3P-CCG and pBAD33 as well as BW25113 
ΔepmB co-transformed with p3LC-TL30-3P-CCG and pBAD33_sRBS_His6_EpmA or 
pBAD33_sRBS_His6_EpmA_A298G, respectively, were grown in 1 L of LB medium at 
37 °C to exponential growth phase. Expression of epmA was induced by 2 g/L 
arabinose and cells were grown at 18 °C ON. Cells were harvested, and the pellet was 
resuspended in TEA buffer. After 30 min of incubation with DNase and PMSF, cells 
were disrupted by a continuous-flow cabinet from Constant Systems Ltd. at 1.35 kb. 
The resulting lysates were clarified by centrifugation for 1.5 h at 4 °C at 235,000 x g. 
Anion Exchange Chromatography was performed using an ÄKTA pure 
chromatography system (GE Healthcare) equipped with Mono Q 10/100 GL and the 
fraction collector F9-C at a salt gradient of 0 to 1 M KCl. The fraction with the highest 
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EF-P concentration was determined by SDS-PAGE followed by Anti-EF-PE.c. Western 
Blotting. Size Exclusion Chromatography was performed using a Superdex 200 
Increase 10/300 GL column. Samples were not analyzed regarding their activity but 
regarding their EF-P modification status, on the one hand by IEF followed by Western 
Blotting, and on the other hand by MS analysis performed by collaboration partners 
(Pavel Kielkowski, TUM).
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3 Results 
3.1 Universal antibody against EF-P of a wide range of bacteria 
The widely used molecular biological technique of Western Blotting is hinged on the 
availability of specific antibodies. The order of polyclonal antibodies against EF-P from 
an unexplored strain is a time- and cost-intensive approach, which is therefore not 
suitable for initial screening experiment. Due to the fact that approximately half of all 
known bacteria are not understood regarding function and modification of EF-P, there 
is a need for an antibody that is specific for EF-P as target protein but at the same time 
nonselective in terms of its bacterial origin.  
EF-Ps of different bacteria show structure and sequence conservation. Primary, 
secondary and tertiary structures of a large set of bacterial EF-Ps were analyzed to 
identify sequence motifs of EF-P that are conserved among as many bacteria as 
possible and at the same time are present on the protein’s surface to represent the 
accessible epitope for an antibody. From these, peptide antibodies were produced 
which were specific, sensitive and universal. The latter can be used to correlate 
Western Blot band intensities and protein amount to finally determine endogenous 
EF-P copy number. Moreover, the antibody is required for detection of EF-P from newly 
studied bacteria on an IEF gel. Separation of endogenous and recombinant EF-P 
according to their charges elucidates occurrence and nature of a potential post-
translational modification. Thereby the universal EF-P antibody subjoins the toolbox 
enabling EF-P research in Gram-positive and Gram-negative bacteria.  
3.1.1 Generation of the two EF-P-specific peptide antibodies P68/P69 
First, the amino acid sequences of EF-P from 1345 different species were downloaded 
from NCBI Knowledgebase [83] in FASTA format. Next, these sequences were aligned 
using two different tools. Clustal W [84] followed by clean-up of sequences with Bioedit 
[85] (excluding sequences with missing domains, improvement of gap alignment) 
identified amino acids with > 90 % conservation. Using CLC Genomics Workbench 7.7 
(https://www.qiagenbioinformatics.com/) consensus sequence was obtained (Figure 
7A). Using The Phyre2 web portal for protein modeling, prediction and analysis [71] 
and the available EF-P crystal structures, four different regions with high density of 
conserved residues were identified that were moreover easily available for antibody 
binding due to their location at the EF-P protein surface (Figure 7B).  
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Figure 7: The four conserved regions of EF-P identified by amino acid alignment of 1345 bacterial 
EF-Ps. Regions 1 - 4 show accumulation of conserved amino acids in the EF-P sequence 
alignment and are highlighted in color. (A) EF-P consensus sequence and secondary structure 
elements. Region 1 contains the residue which is post-translationally modified. Regions 3 and 4 
represent loops between β-strands and were chosen for peptide antibody generation. (B) 
Exemplary EF-P structure (P. aeruginosa) shows accessibility of all four identified regions at the 
protein surface. 
Conserved region 1 (Figure 7, red) consists of the loop between β-strands β3 and β4 
which contains the PTM site, the conserved K32, K34 or R32, respectively. The PTM 
could block the antibody binding and lead to false-negative results. Consequently, this 
region was not taken into consideration for peptide design and synthesis which serve 
as preliminary steps for antibody production. Peptides of regions 2 - 4 included β-
strands and disordered regions. They were analyzed by Eurogentec with respect to 
their predicted antibody quality. As a result, peptides 3 (NH2- 
C+TEPGVKGDTAGGTKP-CONH2) and 4 (NH2-C+VPLFINEGEKIKVDT-CONH2) were 
selected for the Eurogentec Anti-Peptide Polyclonal Antibody program and finally 
yielded antibodies P68 and P69, respectively (Figure 8, Material and Methods 2.2). 
 
Figure 8: Weblogos [86] of the two peptide sequences (P68 and P69) that were chosen for peptide 
antibody production. The high degree of sequence conservation is visualized which formed the 
basis to design the universally applicable EF-P antibodies P68/P69.  
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3.1.2 Characterization of antibodies P68/P69 
The obtained antibodies P68 and P69 as well as their 1:1 mixture were applied in 
Western Blot analysis of purified EF-P from different bacteria. Antibody concentration 
and incubation time were adjusted to define the optimal conditions for laboratory 
application. Moreover, protein amounts were gradually decreased to determine the 
sensitivity for different model organism EF-Ps. 
E. coli, B. subtilis and S. oneidensis were selected as model organisms, not only 
because of their importance in laboratory and commercial work but also due to the fact 
that they encompass three important bacterial PTM types. E. coli as representative of 
the Gram-negative γ-proteobacteria with EpmABC as modification enzymes modifies 
K34 with (R)-β-lysine that is further hydroxylated. B. subtilis was recently postulated to 
be modified with aminopentanol, whereby the full modification pathway is unknown 
[34]. S. oneidensis represents the arginine-type EF-P with R32 being modified with 
rhamnose by the modification enzyme EarP [37].  
Untagged efps of E. coli, B. subtilis and S. oneidensis were overexpressed and purified 
by affinity chromatography. The pure protein as well as bacterial lysates of WT and 
Δefp mutant strains were subjected to SDS-PAGE and subsequently, to Western Blot 
analysis. Three different universal EF-P antibody solutions (P68, P69, and a mixture 
of them) were used in different dilutions (1:100, 1:1,000 and 1:10,000) and incubated 
for different durations (1 h, ON). This detailed antibody characterization is shown in 
Figure 9 and optimal conditions are framed in red.  
For E. coli (Figure 9, upper part), it can be concluded that P69 performed better than 
P68 because here, bands appeared to be more intensiv. Primary antibody in a final 
dilution of 1:1,000 (0.55 μg/mL) and subsequent incubation ON led to the best results. 
EF-P antibodies P68 and P69 were both very sensitive for EF-PB.s.. In this case, a 
mixture used at the highest dilution tested (0.04 μg/mL) was enough to detect EF-P 
from cell lysate. Notably, higher antibody concentrations led to recognition of unspecific 
bands (not shown). Both antibodies P68 and P69 detected S. oneidensis EF-P only in 
the purified and therefore higher concentrated form, whereby P69 at a dilution of 
1:1,000 (0.55 μg/mL) exhibited the best results after ON incubation.  
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Figure 9: Characterization of EF-P antibodies P68 and P69 to find optimal application 
recommendation. SDS-PAGE gel lanes 1 (WT) and 2 (Δefp mutant strain) were loaded with lysate 
of 6·108 cells of E. coli (BW25113, upper part), B. subtilis (middle part) or S. oneidensis (lower 
part), respectively. Each third lane was loaded with 0.5 µg of purified, untagged EF-P. Dilution of 
primary antibody solution was varied, whereby dilution 1:10,000 corresponds to 0.04 μg/mL of 
primary antibody. Optimal antibody dilution and incubation time for each bacterium is framed in 
red. Anti-RABBIT was used as secondary antibody. 
After determination of the best antibody usage conditions for three model organisms 
(also summarized in Table 9), they were applied to quantify the antibody sensitivity. 
Thereby, serial dilution of EF-P starting from 1 μg per SDS-PAGE lane and using a 
dilution factor of two was conducted. Figure 10 shows that EF-PE.c. was successfully 
detected by P69 down to 31 ng (9·1011 molecules) when a dilution of 1:1,000 was used, 
whereas a higher EF-P amount (125 ng) was necessary for proper detection at an 
antibody dilution of 1:10,000. The antibody mixture was highly sensitive towards 
EF-PB.s. as it detected down to 15 ng (4·1011 molecules). For clear detection of EF-PS.o., 
at least 125 ng (4·1012 molecules) were required. Therefore, I suggest this antibody for 
detection of concentrated EF-P.  
The characterization of universal EF-P antibodies P68/P69 showed that both were able 
to specifically detect EF-P of different species. B. subtilis as model organism of Gram-
positive bacteria was sensitively detected by the EF-P antibodies P68/P69. Regarding 
the EF-Ps of the Gram-negative bacteria E. coli and S. oneidensis, P69 clearly 
outreaches P68. S. oneidensis is best detected in the purified form using >0.25 μg of 
protein.  
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Figure 10: Determination of universal EF-P antibody sensitivity towards EF-Ps of E. coli, 
B. subtilis and S. oneidensis. Serial dilution starting at 1 µg of EF-P and reduction by a factor of 
two per lane in the SDS-PAGE gel revealed the minimal EF-P amount necessary for detection by 
the universal EF-P antibody. Optimal antibody and incubation time for the different bacteria was 
determined above and is indicated on the left. 
By that an alternative to the available, organism-specific EF-P antibodies was found 
which does not recognize a tag but endogenous motifs of EF-P that are conserved 
among bacterial species.  
3.1.3 Applications of P68/P69  
3.1.3.1 Determination of endogenous EF-P copy numbers 
Applications of the newly available EF-P antibodies to bacterial lysates enable 
determination of endogenous EF-P copy numbers.  
An EF-P dilution row starting from 1 μg of purified protein as well as bacterial lysate 
with known optical density was loaded on a single SDS-PAGE gel. Grey density 
analysis of the anti-EF-P Western Blot bands were plotted against the corresponding 
EF-P amounts. Exemplary, this is shown for E. coli and B. subtilis in Figure 11A.  
The latter depicts the proportionality between EF-P amount and Western Blot band 
intensity over a wide range. Therefore, the universal EF-P antibodies were suitable to 
determine the linear fit which enables calculation of the amount of EF-P in the WT 
lysate 𝑚𝐸𝐹−𝑃. Application of Equation 2 reveals the number of EF-P per cell 𝑁𝐸𝐹−𝑃. 
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Figure 11: Determination of endogenous EF-P copy numbers. (A) EF-P calibration curves for 
E. coli (P69, 1:1,000) and B. subtilis (Mix, 1:10,000) generated from serial dilution rows shown in 
Figure 10 (single replicate). Grey densities of Western Blot bands were quantified using ImageJ. 
Band intensities for WT lysates of 6·108 cells are highlighted in red. Copy numbers were 
calculated according to Equation 2. (B) Comparison of EF-P copy number for E. coli (red) with 
22 literature values (grey) determined at different conditions and derived from Schmidt et al. [1]; 
represented as Tukey whisker plot. Copy number determined at ‘1 day stationary phase’ is 
shown in black. 
Equation 2: Calculation of endogenous EF-P copy number. 
𝑁𝐸𝐹−𝑃 [
𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠
𝑐𝑒𝑙𝑙
]  =
𝑚𝐸𝐹−𝑃[𝑔] ∙ 𝑁𝐴 [
𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠
𝑚𝑜𝑙
]
109 [
𝑐𝑒𝑙𝑙𝑠
𝑚𝐿 ] ∙  𝑂𝐷600 ∙ 𝑉𝑝𝑒𝑟 𝑙𝑎𝑛𝑒
[𝑚𝐿] ∙ 𝑀𝐸𝐹−𝑃 [
𝑔
𝑚𝑜𝑙
]
 
Using Equation 2 the number of EF-Ps per cell was found to be 7360 for E. coli and 
6717 for B. subtilis and therefore exhibited similar quantities. Schmidt et al. determined 
EF-P copies at 22 different growth conditions of E. coli [1]. Figure 11B shows that EF-P 
copies determined at ‘1 day stationary phase’ by them (8323 EF-P/cell) match the 
determined number in this thesis very well. Muntel et al. analyzed the proteome of 
B. subtilis during exponential growth in an amino acid based medium and found a low 
number of 2274 EF-P/cell [87]. The difference to the value determined in this study 
could origin from divergent cultivation. 
A quick and accurate approach for EF-P copy number determination is shown for, but 
is not limited to, E. coli and B. subtilis.  
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3.1.3.2 Extension of the universal EF-P antibody application to other 
bacteria 
The newly available antibodies P68/P69 were applied to EF-Ps from organisms with 
little research on their EF-Ps. 
 
Figure 12: Application of the universal EF-P antibodies on different bacterial lysates. Bacterial 
lysates (4·108 cells) of Bacillus subtilis (B. s., control), Streptomyces venezuelae (S. v.), 
Streptomyces griseus (S. g.) and Micrococcus luteus (M. l.) were subjected to SDS-PAGE. 
Western Blot was conducted with P68/P69 antibody mixture used in a dilution of 1:1,000 each 
and incubated ON. A sensitive and highly specific reaction is achieved for two Streptomyces 
species and M. luteus. Anti-RABBIT was used as secondary antibody. 
Figure 12 shows that Streptomyces venezuelae, Streptomyces griseus and 
Micrococcus luteus EF-P were detectable from bacterial lysate using a P68/P69 
mixture and simultaneously proof the high specificity of the antibodies as only a single 
band appears on the Western Blot at the expected ~25 kDa size. It is frequently 
observed that some bacterial EF-Ps (S. oneidensis, M. luteus, …) appear at higher 
positions in an SDS-PAGE gel than expected from their amino acid chain length. 
Application of the generated antibodies to other bacterial lysates showed, that 
especially EF-P from Gram-positive bacteria represented by the phyla Firmicutes and 
Actinobacteria were robustly detected. As EF-Ps of these branches of bacteria are not 
adequately studied to date, the universal antibody provides a suitable new tool.  
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3.2 Isoelectric focusing for detection of the post-translational 
modification status of EF-P in vivo 
The electrophoresis method IEF separates proteins on the basis of their different pI 
values. As separation of unmodified and modified EF-P/eIF5A ((R)-β-lysylated [32], 5-
aminopentanolated [36], hypusinated [88]) has been described it appears to be an 
useful technique in the research on PTMs. Nevertheless, a detailed analysis of the 
opportunities and possibilities offered by this technique in the research on PTMs, and 
especially on EF-P is lacking to date. Therefore, I established the IEF method in our 
laboratory. There are vertical, native horizontal and denaturating horizontal IEF, all 
three different techniques being necessary to satisfy the demands of diverse samples. 
This study reveals the intrinsic characteristics of each technique as well as their field 
of application. 
3.2.1 General remarks for reproducible IEF results 
In general, horizontal IEF was preferred over vertical IEF when a complex protein 
mixture is analyzed like it is the case for bacterial lysates. The advantage of vertical 
IEF in comparison to horizontal IEF laid in its easier handling, versatile and cheap 
equipment and shorter focusing time. For reproducible results the experimental setup 
was important for the final position of the protein band to be studied. Consequently, a 
protein standard ladder was found not to be useful in IEF of EF-P because narrow pH 
gradients were applied (e.g. pH 4 - 7 for vertical, pH 4 – 6.5 for horizontal IEF). Instead, 
positions of the bands should always be compared to known controls (EF-Punmodified, 
(R)-β-lysylated EF-P (EF-PRβlys), …). Not least because of the connection between 
temperature and pI it is important to maintain constant and uniform heat transport 
which was ensured by use of a thermostatic circulator (horizontal IEF) or by operating 
the gel in a cold room (vertical IEF). Moreover, it is known that the temperature in 
electrode regions can rise especially during the prefocusing phase of a horizontal gel 
in which the pH gradient is established [89]. Therefore, samples were applied after the 
prefocusing step to prevent them from overheating. Although proteins can travel in 
both directions between cathode and anode in this electrophoretic technique, it is very 
important to find the appropriate sample application location. By applying cell lysates 
to different gel regions (cathode side, middle, anode side), it became very clear that 
lysates should always be applied at the cathode side to ensure good resolution of the 
different protein bands (not shown). In general, the application location should be kept 
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at a distance of at least 1 cm to the electrodes to avoid extreme pH, and optimally lays 
near the place where the interesting protein band was about to settle.  
The native horizontal IEF gels shown in Figure 13BC reveal the positioning of the EF-P 
band in a gel with established pH gradient from 4 - 6.5 (rehydration of the gel with 
Pharmalyte (GE), see Materials and Methods 2.6.3). It shows that (R)-β-lysylation of 
EF-P is clearly distinguishable from unmodified EF-P in the purified samples (B) and 
in the lysate (C) due to the fact that it settles in closer proximity to the cathode than the 
variant without PTM.  
 
Figure 13: Native horizontal IEF of EF-P from E. coli BW25113. (A) Schematic depiction of 
horizontal IEF performed in flat-bed apparatus. Horizontal gels are appropriate for ambitious 
specifications like gel rehydration with urea or other supplements. The figure is adapted from 
Serva Electrophoresis Seminar (02.03.2017). (B, C) The entire width of the native horizontal IEF 
gel is shown to reveal the exact positioning of EF-P in the tagged/endogenous and 
unmodified/modified form. Proteins were stained unspecifically by Silver Staining (upper part) 
or subjected to Western Blot incubated with Anti EF-PE.c. (lower part). The theoretical pI value 
5.17 of endogenous unmodified EF-P is indicated. (B) 2 µg of purified, His6-tagged EF-P 
overproduced in WT or E. coli ΔepmA were loaded per lane. (C) Lysate of 1·108 cells of WT and 
E. coli ΔepmA were loaded per lane. 
Although only a single additional positive charge originating from the β-amino group of 
the PTM is present, which does not influence the theoretical pI value so much, the 
electrophoretic behavior is altered which leads to distinguishable bands and makes the 
IEF technique very useful for PTM research. The theoretical pI value of EF-Punmod in 
the endogenous and His6-tagged form vary by only 0.01 pH units (calculated by 
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ExPASy pI/Mw tool). Unexpectedly, it becomes obvious from Figure 13BC that 
untagged and tagged protein have a distinct settling point in the gel.  
Due to high influence of the protein tag on the electrophoretic behavior in the IEF gel 
it is necessary to purify EF-P in unaltered form to use it as control in experiments 
involving lysates. If, however, the status of tagging or PTM of purified EF-P should be 
determined, vertical IEF is conducted (Figure 14A).  
 
Figure 14: Vertical IEF reveals status of purified EF-Ps. (A) Schematic depiction of a vertical IEF 
chamber. The vertical system is suitable for quick and easy applications. The figure is adapted 
from GE Multiphor II manual. (B) Verification of amino acid replacements (K34R, P32S, 5 µg EF-P 
per lane) and completed protease digest. (C) Modification status detection of EF-P expressed in 
different E. coli strains (3 – 10 µg per lane). In an epmA deletion (-) strain, fully unmodified EF-P 
was produced (+, endogenous expression). Deletion of epmC (-) led to production of 
unhydroxylated EF-P but also to a similar portion of unmodified EF-P. Plasmid-based 
overexpression (++) of epmA and epmB ensures PTM of EF-P. 
Due to the finding of distinct running behaviors of tagged and untagged EF-P, protein 
SUMOylation was chosen to produce untagged EF-P in high amounts (see Material 
and Methods 2.4). Affinity purification of His6-SUMO-EF-P was followed by scar free 
cleavage by the help of SUMO protease Ulp (ubiquitin-like protein-processing enzyme) 
to finally produce untagged EF-P. The latter can be used as control for analysis of 
EF-P modification status during different E. coli growth phases (Chapter 3.2.2).  
Moreover, Figure 14B shows the successful and complete cleavage of the SUMO-tag 
which was ensured by quick and easy application of vertical IEF. Different EF-P 
variants of E. coli (K34R, P32S) were shown to be unmodified before these variants 
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could be used for interaction studies with EarP from P. putida. Depending on the 
overexpression strain, EF-P of E. coli can exhibit a different PTM status. As already 
shown above, efp expression in E. coli ΔepmA exclusively yields EF-P in the 
unmodified state (Figure 14C). Simultaneous overexpression of efp and epmA 
primarily leads to unmodified EF-P (reported in [24]), whereby primarily modified EF-P 
is examined when modification systems epmAB were overexpressed (Figure 14C). 
Deletion of epmC leads to unhydroxylated EF-P, which reportedly has no negative 
impact on EF-P functionality [16, 20]. Interestingly, vertical IEF reveals that EF-P is in 
the modified as well as in the unmodified state suggesting a potential role of the 
hydroxylation in the protection of the PTM.  
Horizontal IEF is the technique of choice, when lysates need to be analyzed regarding 
the modification status of EF-P whereas vertical IEF is the suitable tool for analysis of 
purified EF-P samples.  
3.2.2 Detection of EF-PE.c. modification status in different growth phases 
Newly biosynthesized EF-P in the cytosol of E. coli is transmitted to EpmA and accepts 
(R)-β-lysine to be ligated to K34. Either repletion of EpmA and EpmB ensures complete 
EF-P modification during all phases of growth, or a bottleneck on the PTM pathway 
occurs, which would lead to partially unmodified endogenous EF-P. To test this, five 
representative in vivo samples, namely from lag phase, exponential growth phase and 
stationary phase were collected (Figure 15A). Proteins from corresponding lysates 
were resolved by SDS-PAGE (Figure 15C) and subsequently, grey density analysis 
revealed the relative protein amount per lane that is equalized in the next step. Then, 
the lysates were subjected to native horizontal IEF (pH 4 - 6.5). Figure 15D reveals 
that during all phases, EF-P is present in the post-translationally modified form.  
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Figure 15: Native horizontal IEF reveals modification status of E. coli EF-P during different 
growth phases. (A) Growth curve of E. coli BW25113 with sample collection over 24 h. Five 
timepoints were chosen for further analysis (highlighted in red) which represent the different 
growth phases. OD600 of lysates were set to 10. (B) Abbreviations of growth phases. (C) SDS-
PAGE (1.6·108 cells per lane) with protein visualization by TCE (2,2,2-trichloroethanol) staining 
[78]. Relative protein amounts were determined by Image Lab Software 4.1 (Bio-Rad) to load 
equal protein amounts on the IEF gel. (D) Western Blot of native horizontal IEF gel. Pure 
untagged EF-P (5 µg per lane) in the modified and unmodified form served as controls. All five 
analyzed endogenous EF-P samples show complete PTM. Anti-EF-PE.c. was used to detect EF-P.  
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3.3 Modification of EF-P with unnatural substrates by the help of EpmA 
3.3.1 Copy number balance of EF-P, EpmA and EpmB 
Analysis of the EF-P modification state in vivo at different growth phases of E. coli 
showed complete PTM at all growth stages. Therefore, the question arises if EpmA 
and EF-P copy numbers are finely tuned or if excess of EpmA prevents the occurrence 
of EF-P in the unmodified state. Therefore, EF-P-to-EpmA ratios were varied in E. coli 
and subsequently, EF-P’s modification status was analyzed by vertical IEF. Moreover, 
the EF-P amino acid variant K34R was included to test acceptor substrate specificity 
of EpmA. Then, EF-P-to-EpmA/EpmB ratios at different growth conditions from 
literature values were summarized. 
Figure 16A (previously partially published in [38]) shows that deletion (-) of epmA in 
the expression strain led to fully unmodified EF-P. A 2:1 ratio of EF-P-to-EpmA was 
investigated by chromosomal introduction of a second EF-P copy. The latter was made 
possible using E. coli LF1 Plac efp as this strain harbored an additional, His6-tagged efp 
copy at Plac locus. Interestingly, endogenous levels of EpmA (+) only modify half of the 
EF-P portion, when a second copy of EF-P was introduced (2x). Here, vertical IEF gel 
exhibited two bands with similar strength indicating 50:50 distribution of EF-Pmod/EF-
Punmod. This result underlines that EpmA und EF-P copies were finetuned to ensure 
complete modification in WT cells at the same time avoiding energy consuming 
oversupply with modification enzyme. Endogenous EpmA amounts were not sufficient 
to post-translationally modify EF-P, when the gene was overexpressed using an 
arabinose-inducible promoter, whereas additional EpmAB overproduction ensured 
complete modification which is shown in the vertical IEF gel by appearance of a single 
band shifted towards the cathode.  
By contrast, amino acid variation of K34 to arginine, which is the corresponding amino 
acid in EarP modifying bacteria, prevented PTM at this residue in E. coli independent 
of EpmA-to-EF-P ratio. This indicates the acceptor substrate specificity of EpmA.  
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Figure 16: EF-P and EpmA copy numbers are balanced to each other. (A) Variation of EF-P-to-
EpmA copy numbers with subsequent analysis of EF-P modification state by vertical IEF. 0.5 µg 
of EF-P was loaded per lane. EF-P and EpmA copy numbers were modulated by gene deletion 
(-), endogenous expression (+), introduction of an additional gene copy (2x) and plasmid-based 
overexpression of EpmAB (++). In addition to E. coli EF-P, the amino acid variant EF-P_K34R 
was tested. Modified and unmodified EF-Ps were separated in the vertical IEF gel and visualized 
by Western Blotting incubated with Anti-EF-PE.c.. (B, C) Copy number ratios of EF-P and EpmAB 
determined by Schmidt et al. [1]. EF-P-to-EpmA (B) and EF-P-to-EpmB (C) copy numbers of 22 
growth conditions were determined by Schmidt et al. and ratios are presented as whisker plot. 
Here, outliers are labeled with the specific growth condition. 
Schmidt et al. [1] analyzed copy numbers of EF-P, EpmA and EpmB at 22 different 
growth and stress conditions in E. coli. Their results are graphically represented in 
Figure 16BC and show that there is one EpmA molecule per approximately 550 EF-Ps 
(median of the whisker plot). This value is quite stable at all tested conditions except 
for growth in the chemostat reactor with the specific growth rate of µ=0.12, because 
here copy numbers are low in general. EF-P-to-EpmB ratios vary more drastically. At 
average conditions, one EpmB molecule supplies 650 EF-Ps (median of the whisker 
plot). Interestingly, EpmB was not found in every cell at stationary phase, leading to 
the high calculated ratio in Figure 16C. After one and three days, 0.2 and 0.03 copies 
per cell were measured, respectively [1]. Therefore, the question arises how and if 
EF-P is modified when EpmB is not present in the cell and can not ensure supply with 
(R)-β-lysine.  
In summary, the copy numbers of EF-P and EpmA appear to be finely tuned in E. coli. 
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3.3.2 Identification of functional EpmA amino acid variants 
It is known that LysRS is the most promiscuous of all aaRSs, which is underlined by 
the fact that tRNALys is mischarged with arginine, threonine, methionine, leucine, 
alanine, serine and cysteine in vitro [54]. Yanagisawa et al. [24] and Roy et al. [32] 
reported several amino acid to alanine substitutions of EpmA which led to loss of 
function or significantly reduced lysylation activity. Outstanding is the alanine 298 (E. 
coli numbering) to glycine variant because here, donor substrate affinity is altered from 
(R)-β- to (S)-α-lysine by just exchanging one amino acid in the catalytic pocket [32].  
The aim was to identify more functional EpmA variants by an adaptive evolution 
experiment using E. coli ΔepmB that is unable to produce (R)-β-lysine. The 
dependence on functional EF-P for fitness was achieved by introduction of an 
additional triproline motif which was cloned upstream of the neomycin 
phosphotransferase I gene (nptI) that is responsible for resistance to kanamycin. A LB 
agar plate with gradually increasing kanamycin concentration was coated with E. coli 
ΔepmB transformed with the above described plasmid as well as a plasmid-based 
copy of epmA. Growth at higher kanamycin concentrations was possible for clones that 
overcame the strong ribosome stalling motif by bringing EF-P into the functional form 
without having (R)-β-lysine, then properly translating nptI and thereby gaining 
resistance to kanamycin. By that approach, five clones were identified that were able 
to grow at higher kanamycin concentrations (Figure 17A) and those were subjected to 
a second round of growth on the kanamycin gradient plate. Figure 17B shows that only 
colonies 2, 4 and 5 retained the phenotype. Sequencing of genomic efp and the 
extracted plasmid neither revealed mutations causing amino acid alterations in EF-P 
nor in the catalytic pocket of EpmA. Beside the opportunity of mutating PPP-nptI, it has 
already been described that there are ways to bypass EF-P dependence. For example, 
it was proposed in Erwinia amylovora that hrpA3 deactivation decelerates mRNA 
degradation at stalled ribosomes to allow more time for translation processes [90]. 
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Figure 17: Directed evolution experiment to identify functional EpmA variants. (A) BW25113 
ΔepmB was double transformed with a plasmid harboring the kanamycin resistance gene nptI 
that included a triproline motif, and a plasmid-based copy of epmA. During the first round of 
selection, five colonies (encircled in red) were able to grow at higher kanamycin concentrations. 
(B) Bar graph. Colonies from (A) were quantified (white bars) as well as their performance in a 
second round of growth on a kanamycin gradient plate (grey bars). Colony 2, 4 and 5 kept the 
kanamycin resistance phenotype in the second round but sequencing showed that neither efp 
nor the catalytic pocket of epmA was mutated. For the second round, standard errors of 
technical duplicates are shown.  
Due to the unsatisfying results from the approach with PPP-nptI and to avoid the 
opportunity of mutating the triproline motif as strategy to relieve the EF-P dependence, 
gentamicin sensitivity was chosen as evolutionary pressure and fitness advantage 
readout. It was reported that ΔepmA and ΔepmB mutants of Salmonella enterica 
serovar Typhimurium 14028s are more susceptible to the aminoglycoside gentamicin 
than the WT strain [44, 91]. Again, E. coli ΔepmB was used to prevent (R)-β-lysine 
attachment by EpmA, instead substrate promiscuity of EpmA should be utilized to 
functionalize EF-P in a non-cognate way. Therefore, EpmA copy number was 
increased by addition of arabinose to the agar plate that ensured additional expression 
of epmA from pBAD vector.  
The seven colonies that grew at highest gentamicin concentrations were picked from 
gradient plates incubated with BW25113 ΔepmB and MG1655 ΔepmB, respectively. 
Sequencing proved that efp was unmutated in all these colonies. Interestingly, amino 
acid residue R303 which is part of the catalytic pocket of EpmA was mutated in several 
of the colonies at the first two codon positions (Figure 18A). By these mutations, three 
amino acid exchanges were indicated, namely R303 to serine, leucine or isoleucine. 
Figure 18B illustrates proximity of this residue to the activated donor substrate (R)-β-
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lysyl-AMP. All these epmA mutants with amino acid exchanges were cloned into 
pBAD33 and were subjected to kanamycin gradient plates containing an additional 
plasmid with PPP-nptI. As results from Figure 18C indicate, PPP-nptI was expressed 
equally well in all strains except for EpmA which was able to grow at slightly higher 
kanamycin concentrations. Unfortunately, none of the EpmA variants tested exhibited 
increased antibiotic resistance and therefore EpmA and the reported EpmA_A298G 
enzyme variant were used in the following study.  
 
Figure 18: Determination of functional EpmA variants. (A) Exemplary sequencing result of 
colonies obtained at high gentamicin concentrations in E. coli ΔepmB background. EpmA 
residue R303 is encoded by CGT and shown to be mutated at the first and second codon. As 
consequence, plasmids with epmA containing the amino acid exchange mutations R303 to 
serine, leucine and isoleucine were created. (B) View into the catalytic pocket of EpmA shows 
the proximity between EpmA (orange) residue R303 (red), EF-P (light blue) and the ligand (R)-β-
lysine (dark blue). (C) Bar graph of the growth behavior of different strains on kanamycin 
gradient plates. -: empty pBAD vector. Shown is the standard error of biological duplicates.   
3.3.3 Unnatural post-translational modifications of EF-P mediated by 
EpmA 
Ambrogelly et al. [51] analyzed the substrate spectrum of LysRS paralog EpmA, 
without knowing the cellular function of this enzyme. Accordingly, they selected 
different α-amino acids like 5-hydroxy-(S)-α-lysine, (S)-α-lysine, DAP and thialysine 
((S)-(2-aminoethyl)-L-cysteine) [51]. Having demonstrated the substrate promiscuity to 
be valid for these compounds, I now analyzed the substrate specificity in detail 
because the role of EpmA in EF-P modification pathway and the fact that (R)-β-lysine 
serves as donor substrate has been solved [19, 32]. The question arises which 
chemical groups of the cognate substrate (R)-β-lysine are necessary for recognition 
and conversion by EpmA. Comprehensive approaches depicted in Figure 19 were 
selected to get a deep understanding of the sterical prerequisites necessary for EpmA 
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to recognize, activate (aa-AMP formation) and finally transfer the donor substrate to 
acceptor EF-P of E. coli.  
 
Figure 19: Schematic depiction of in vitro modification reaction to create synthetically modified 
EF-P. (A) In vitro activation of non-cognate substrates (indicated by colored stars) by EpmA and 
EpmA_A298G. Progress of the reaction was visualized by separation of [α-32P]-ATP (ATP*) from 
[32P]-AMP (AMP*) which indicates hydrolysis of ATP that occurs parallel to aminoacyl adenylate 
(glowing stars) formation. Quantification by thin layer chromatography (TLC) followed by 
autoradiography enabled Km determination. (B) In vitro ligation of non-cognate donor substrates 
to EF-P. 25 µM purified unmodified EF-P, 5 µM pure EpmA(_A298G) and 10 mM potential donor 
substrate were incubated ON. Successful in vitro modification of EF-P is visualized by distinct 
running behavior on the vertical IEF gel or by MS analysis.  
Several different compounds structurally derived from (R)-β-lysine were subjected to 
in vitro activation by EpmA. The formation of aminoacyl adenylate occurs in parallel to 
hydrolysis of radioactively labeled ATP. Therefore, occurrence of radioactively labeled 
AMP could be separated from ATP by TLC which is followed by autoradiography and 
therefore enables quantification of activation of the non-cognate substrates of EpmA. 
In a second experiment, the successfully activated lysine derivatives were subjected 
to in vitro EF-P modification (Figure 19B). 
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3.3.3.1 Selection of enzyme variants and several possible EpmA substrates for 
in vitro EF-P modification reaction 
To elucidate which part or moiety of the natural substrate (R)-β-lysine is important for 
recognition and activation by EpmA, the set of lysine derivatives depicted in Figure 20 
was chosen. The sterical variations compared to the natural substrate are indicated 
and their biological relevance revealed.  
Beside both enantiomers of α- and β-lysine substrates with shortened carbon chain 
((S)-α-ornithine, (R)-β-ornithine) were included in the study. Polarity was altered by 
hydroxylation (5-hydroxy-(S)-α-lysine) or by deamination of the natural EpmA 
substrate (3- and 6-hexanoic acid (capronic acid, AC)). Also here, enantiopure 
substrates ((R)-3-AC, (S)-3-AC) were used to elucidate stereoselectivity of EpmA. 
Moreover, DAP being an important precursor for lysine biosynthesis in bacteria was 
tested. The list includes highly abundant cellular compounds like (S)-α-lysine (0.4 mM) 
and (S)-α-ornithine (0.01 mM) [92] but also compounds which are to the best of my 
knowledge unknown in bacteria.   
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Figure 20: Potential EpmA substrates tested in this study. Chemical structure, trivial name and 
biological relevance are listed. Structural alterations compared to (R)-β-lysine are highlighted in 
orange. Carbon chain shortening is indicated by C-atom numbering. Names or abbreviations 
used in this study are indicated in bold. [93], [94], [95], [96, 97], [98], [99], [100] [101] 
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Having selected potential substrates for EpmA, EpmA_A298G was also chosen as 
enzyme variant to get a deeper understanding of the interplay between the amino acid 
residues of EpmA’s catalytic pocket and the ligand.  
It is known that LysRS and EpmA differ in two relevant amino acids in the catalytic 
pocket. The amino acid residues alanine 298 and serine 76 of EpmA are crucial for 
specificity, substrate recognition, substrate binding and enzymatic activity [32]. Here, 
mutation of serine 76 to alanine abolishes EpmA functionality [32]. The amino acid 
residue at position 298 is determining the structure of the ligand which is also 
demonstrated schematically in Figure 21AC. WT EpmA with alanine 298 (Figure 21A) 
has evolved towards (R)-β-lysine as enzyme-ligand spacings are adapted to each 
other. Absence of the methyl group as amino acid side chain - like it is the case in 
LysRS or in the EpmA variant with glycine at position 298 - creates space for α–lysine 
and its structural derivatives (Figure 21C). A sterical clash between the methyl group 
of alanine 298 and the amino group of an α amino acids is unfavored.  
 
Figure 21: Residue 298 of EpmA regulates donor substrate specificity. Km determination and 
zoom into the catalytic pocket of EpmA (A, B) and EpmA_A298G (C, D). (A) Schematic zoom into 
the catalytic pocket of the WT enzyme-substrate combination: EpmA and (R)-β-lysine. The white 
halo enlightens residue 298. (B) In vitro activation of (R)-β-lysine (blue) and (S)-α-lysine (green) 
were detected by hydrolysis of ATP forming AMP. Km of (R)-β-lysine for EpmA laid in the low mM 
range. (C) Amino acid variation A298G created free space in the catalytic pocket of EpmA that 
led to increased affinity toward (S)-α-lysine compared to WT EpmA. (D) Substrate specificity of 
EpmA_A298G was shifted toward (S)-α-lysine representing this enzyme’s low Km substrate.  
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This was demonstrated when kinetics were determined using the in vitro substrate 
activation assay which is equally structured than tRNA charging assays of aaRSs 
(Figure 19A, described in detail in the following chapter). Successful activation of the 
substrate by EpmA or EpmA_A298G was indicated by release of AMP. Figure 21B 
shows that addition of (R)-β-lysine (shown in blue in all figures) as substrate led to 
detectable AMP release at low millimolar concentrations, whereas in this concentration 
range, activation of (S)-α-lysine (shown in green) was undetectable. Km of the natural 
enzyme-substrate combination was determined to be 0.23 mM. Induced by amino acid 
substitution A298G, the substrate specificity from (R)-β- to (S)-α-lysine was shifted and 
is visualized in Figure 21D. Km for (S)-α-lysine was low (0.065 mM) and activity was 
shifted at the expense of affinity towards (R)-β-lysine. 11 potential donor substrates 
were selected to be tested in combination with EpmA (low Km substrate: (R)-β-lysine) 
and EpmA_A298G (low Km substrate: (S)-α-lysine). 
3.3.3.2 Determination of kinetic parameters for in vitro activation of non-cognate 
substrates by EpmA 
The most important steady state kinetic assays for aaRSs are the pyrophosphate 
assay and the aminoacylation assay, respectively [102]. Both options were tested, and 
it was found that Pyrophosphate Assay Kit II (Fluorometric, Abcam) responded to 
EpmA without substrate as well as to substrate without having added any enzyme (not 
shown) and is therefore not applicable for the purpose of this thesis. Therefore, the 
classical assay for tracking of tRNA charging already established decades ago [56] 
was used in which purified enzyme (aaRS/EpmA), donor substrate (amino acid), ATP 
and a portion of [α-32P]-ATP was incubated at 37 °C. The reaction was quenched 
subsequently. Activation of the donor substrate led to simultaneous ATP hydrolysis. 
Unreacted [α-32P]-ATP and newly formed [32P]-AMP were separated by TLC and 
detected by autoradiography. Grey density quantification of the autoradiography 
plates, exemplary shown in Figure 22, revealed several findings.  
First, detectable AMP release over time shows that 6-AC was accepted as substrate 
by EpmA. The latter readily activated 6-AC although at this compound, a β-amino 
group is absent. Therefore, EpmA tolerates structural alterations of its natural substrate 
(R)-β-lysine and obviously does not require the β-amino group for substrate 
recognition.  
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Second, it is demonstrated that the aa-AMP intermediate is formed independently of 
an acceptor substrate (0 or 5 µM EF-P), so addition of EF-P did not alter the amino 
acid activation by EpmA. This fact was also reported by Francklyn et al. for most 
aminoacylation reactions examined, except for GlnRS, GluRS and ArgRS [102]. It 
allows focus on the first substep of EpmA catalysis excluding acceptor substrate 
effects and is important for understanding prerequisites of donor substrate binding or 
exclusion in detail.  
 
Figure 22: tRNA charging assay implemented to detect non-cognate substrate activation by 
EpmA. Exemplary, 6-AC was chosen as substrate. In vitro aa-AMP formation catalyzed by EpmA 
was followed over time (0 - 60 min). Technical duplicates of each time point were spotted to TLC 
plates. Grey densities of the audiographs (right side, representative) were analyzed. For 
quantification, Equation 1 (Material and Methods, Chapter 2.11) was used. 6-AC was activated by 
EpmA, irrespective if EF-P was absent (dots) or added (squares). 
Having shown that the tRNA charging assay described above is suitable for 
determination of kinetic parameters for substrate activation by EpmA, 15 min was 
chosen as fixed timepoint and simultaneously substrate concentration was varied. ATP 
was present in excess which allowed approximation of the enzymatic reaction to a 
single-substrate mechanism. This allowed for Km determination by fitting the obtained 
curve according to Michaelis-Menten equation [103]. In addition to the cognate 
enzyme-substrate pairs (already shown in Figure 21, substrate concentration 0 - 
2.5 mM), concentrations of non-cognate substrates were varied between 0 and 
100 mM to follow the progress of the in vitro substrate activation (Figure 23).  
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Figure 23: Km value determination for EpmA and EpmA_A298G. Michaelis-Menten kinetics are 
shown for EpmA (A) and EpmA_A298G (B) for different lysine derivatives. Whenever possible, 
Km value was determined. Although (R)-3-AC served as substrate for EpmA, Km determination 
was not accurately possible for EpmA as well as EpmA_A298G because of substrate inhibition 
effects at high (R)-3-AC concentrations and improper saturation at low substrate concentrations. 
Plotted is the standard error of technical duplicates.  
From these kinetic curves it became apparent that (R)- and (S)-α-lysine, 5-hydroxy-
(S)-α-lysine, (R)-3-AC and 6-AC can be activated beside the natural EpmA substrate 
because for all of them distinct amounts of [32P]-AMP were released. Only (S)-α-
ornithine, (R)-β-ornithine, DAP and (S)-3-AC showed no detectable activation by EpmA 
in the explored concentration range. These data underline the stereoselective choice 
that EpmA was able to make as it activated (R)- but not (S)-3-AC. 
Table 5 summarizes the completive set of Km values for the 11 tested substrates and 
the two different enzyme variants. The EpmA_A298G variation was previously shown 
to reduce the Km value towards (S)-α-lysine by 96 % compared to WT [32]. Fittingly, 
only the enzyme-substrate pairs EpmA + (R)-β-lysine and EpmA_A298G + (S)-α-lysine 
exhibited Km values below 1 mM, all other unnatural substrates showed Km values in 
the millimolar range. Km[(S)-α-lysine] of 5 mM (EpmA) and 65 μM (EpmA_A298G) 
were in line with data from Roy et al. who found 9 mM (EpmA) and 344 μM 
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(EpmA_A298G) [32]. In the same publication they found quite similar Km values for (R)-
β-lysine regarding both enzyme variants (213 and 414 μM). The values determined 
here varied by a factor of 60 which appears consistent and explicable. (R)-β-lysine 
exhibited a Km value of 18 μM for EpmA and a much higher value of 11 mM for 
EpmA_A298G because here, substrate specificity is shifted towards (S)-α-lysine at the 
expense of (R)-β-lysine.  
Table 5: Km values for different substrates of EpmA and EpmA_A298G. 
Km [mM] 
enzyme 
EpmA EpmA_A298G 
(R)-β-lysine 0.23 (±0.07) 10.8 (±4.0) 
(S)-β-lysine Not determined 
(R)-α-lysine 20.5 (±9.3) 7.2 (±2.0) 
(S)-α-lysine 5.2 (±1.3) 0.065 (±0.032) 
(R)-3-aminohexanoic acid Not estimable 
(S)-3-aminohexanoic acid No reaction 
(R)-β-ornithine No reaction 
(S)-α-ornithine No reaction 10.8 (±4.1) 
6-aminohexanoic acid 1.8 (±0.8) No reaction 
diaminopimelic acid No reaction 
5-hydroxy-(S)-α-lysine 36.1 (±6.4) 6.8 (±1.7) 
 
Km values for (R)-3-AC and for (S)-β-lysine could not be determined. (R)-3-AC 
exhibited substrate inhibition effects in vitro that led to a reduction of AMP formation at 
concentrations above ~10 mM. As a result, saturation was not reached which 
prohibited exact curve fitting and Km determination. Moreover, it induced a growth 
defect in vivo (Figure 24). For (S)-β-lysine, determination of the stock solution 
concentration was not accurately possible. The Km value was determined in [32] to be 
6.95 mM. 
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Figure 24: Growth of E. coli BW25113 ΔepmB in LB medium supplemented with different 
concentrations of (R)-3-AC. Cells exhibit a growth defect at concentrations above 1.25 mM. 
The detailed analysis of Km values furthermore shows that regarding the α-amino acid 
derivates (R/S)-α-lysine and 5-hydroxy-(S)-α-lysine, Km values were significantly lower 
(factor 3 – 80) for EpmA_A298G than for EpmA. Even more striking, (S)-α-ornithine 
could not be activated by the WT enzyme but only by EpmA_A298G. The latter evolved 
towards α-amino acids but remarkably the shortage of the carbon chain by one carbon 
atom affected the Km value by several orders of magnitude as Km[(S)-α-lysine] = 65 μM 
and Km[(S)-α-ornithine] = 10 mM. EpmA_A298G not only tolerated the α-amino group 
at different lysine derivatives, it even seemed to require it for activation of the substrate. 
This was indicated by 6-AC, a compound where no α- nor β-amino group was present. 
It was readily activated by EpmA (even exhibiting a low Km value around 2 mM) but 
showed no reaction when EpmA_A298G was present. Absence of the ε-amino group, 
represented by (R)-3-AC, did not abolish function of EpmA and EpmA_A298G.  
By determination of kinetics for activation of 11 lysine derivatives by EpmA and 
EpmA_A298G useful insights into the amino acid promiscuity and specificity of the 
enzymes regarding the successful condensation reaction with AMP were gained. They 
lead to the conclusion that activation by EpmA requires a 6-atom carbon chain with 
either ε- (6-AC), β- ((R)-β-lysine, (R)-3-AC) or α- ((R/S)-α-lysine, 5-hydroxy-(S)-α-
lysine) amino group. EpmA_A298G explicitly preferred substrates with α-amino groups 
((R/S)-α-lysine, (S)-α-ornithine, 5-hydroxy-(S)-α-lysine), tolerates substrates with β-
amino groups ((R)-β-lysine, (R)-3-AC), but excludes 6-AC. 
3.3.3.3 Creation of new, unnaturally modified EF-P variants 
The selection mechanisms of aaRSs are performed at the stage of amino acid 
activation (pre-transfer editing) as well as subsequent to transfer of an incorrect amino 
acid (post-transfer editing). For the first-mentioned method, non-cognate amino acids 
are eliminated by rejecting false ternary complexes at the ribosome [5]. In contrast, 
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non-cognate amino acids which were already incorporated into the nascent peptide 
are sorted out by recruitment of release factors [104].  
In Chapter 3.3.3.2 seven lysine derivatives were shown to be activated by EpmA and/or 
EpmA_A298G. (S)-3-AC, DAP and (R)-β-ornithine were excluded from activation (pre-
transfer editing). Therefore, the question arises if substrate activation constitutes the 
bottleneck of the reaction and consequently all aminoacyl adenylates can be 
transferred to EF-P, or post-transfer editing prevents EF-P modification with these 
unnatural substrates. To elucidate this second substep of EF-P modification, the 
ligation reaction, lysine derivatives were tested in combination with one of the two 
purified enzyme variants in the in vitro modification assay (schematically depicted in 
Figure 19B). When the lysine derivative is successfully attached to EF-P, its charged 
groups (in this case mostly amino groups) contribute to the pI value of the protein and 
lead to a shift towards the cathode compared to the unmodified input EF-P. 
The Western Blot in Figure 25 confirms that EF-P was successfully modified in vitro by 
(R)- and (S)-β-lysine catalyzed by both enzyme variants because the heights of the 
bands corresponded to the positive control (EF-PRβlys, in vivo modified). This leads to 
the conclusion that the enantiomer of the natural EpmA substrate was readily activated 
and subsequently ligated to EF-P although the β-amino group at the chirality center 
points in a different direction. (S)-α-lysine exhibited a slightly lower but undoubtedly 
EF-P-attached band. This is explicable by the fact that α-amino acids in general show 
a lower pKa value than β-amino acids (e. g. pKa[α-alanine] = 9.87 [105], pKa[β-alanine] 
= 10.24 [106]) because of the stronger inductive effect (–I) of the carboxyl group in the 
case of α-amino acids. EpmA_A298G ligated both α-lysine enantiomers to EF-P 
whereas EpmA only transferred (S)-α-lysine, apparently requiring the amino group to 
point into the same direction than it is the case at the natural substrate.  
The pI value for EF-P modified with 5-hydroxy-(S)-α-lysine was only slightly higher than 
for EF-P in the unmodified state because here the pI elevating effect of the α- and ε-
amino groups were reduced by the diminishing effect of the hydroxyl group. In line with 
expectations, 5-hydroxy-(S)-α-lysine was transferred to EF-P to a certain extent by 
EpmA resulting in an unmodified and a modified band with similar intensities in the IEF 
gel, whereas for the amino acid variant EpmA_A298G the reaction was complete.  
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(S)-glutamine and (S)-arginine were not transferred to EF-P by either of the enzymes. 
This is important for the cell because intracellular concentrations of these compounds 
are high (3.8 and 0.6 mM [92], respectively) and should therefore be excluded by 
EpmA to avoid invalid, energy-consuming EF-P modification.  
 
Figure 25: Vertical IEF shows the non-cognate in vitro modification of EF-P by EpmA and 
EpmA_A298G. For in vitro reaction purified unmodified EF-P and purified enzyme were 
incubated with 10 mM substrate ON. 1.5 µg of EF-P was loaded per lane. Unmodified (marked in 
red) and modified (marked in green) EF-Ps were separated in an IEF gel and visualized by 
Western Blotting (EF-PE.c. antibody). In vivo modified EF-P served as positive control.  
For all tested substances, the modification status of EF-P was also confirmed by MS 
analysis. This was essential for the substrates 3-AC and 6-AC because they do not 
contain additional charged groups compared to K34 so their attachment to EF-P is 
invisible by IEF technique. The mass of unmodified EF-P was subtracted from the 
measured mass resulting in the detected mass shift ∆ which is presented in Table 6. 
Therefore, 𝛥𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 ~1 stands for unmodified EF-P whereas a number ~130 
constitutes EF-P in the modified form. 
 
Equation 3: Calculation of mass shift 𝜟𝒎𝒆𝒂𝒔𝒖𝒓𝒆𝒅 caused by in vitro EF-P modification 
∆𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 = 𝑚(𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑) − 𝑚(𝐸𝐹-𝑃
𝑢𝑛𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑) 
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Table 6: EF-P in vitro modification was elucidated by determination of the additional mass 𝜟. MS 
analysis conducted with intact EF-P after in vitro EF-P modification reveals that eight substrates 
were successfully attached (indicated in green) by either EpmA or EpmA_A298G. Two numbers 
in a lane point up the presence of both modified and unmodified EF-P and therefore stand for 
incomplete PTM status.  
substrate 
Mass shift of 
succesfull PTM 
Δtheoretical 
Mass shift detected after in vitro 
modification 
Δmeasured 
EpmA EpmA_A298G 
(R)-β-lysine 129.19 129.24 
 
129.23 
(S)-β-lysine 129.19 129.24 
 
129.24 
(R)-α-lysine 129.19 1.13 
 129.21 
1.97 
(S)-α-lysine 129.19 130.24 
 129.23 
0.14 
(R)-3-aminohexanoic acid 114.17 113.27 
 
114.22 
(S)-3-aminohexanoic acid 114.17 1.18 
 
1.14 
(R)-β-ornithine 115.14 1.14 
 
1.14 
(S)-α-ornithine 115.14 1.13 
 
114.08 
6-aminohexanoic acid 114.17 114.22 
 
0.13 
Diaminopimelic acid 173.09 1.1.4 
 
1.1.3 
5-hydroxy-(S)-α-lysine 145.19 
145.22 
1.12 
 
145.22 
(S)-arginine 157.20 1.14 
 
1.15 
(S)-glutamine 129.15 1.14 
 
1.14 
 
In line with results from aa-AMP formation, (S)-3-AC does not serve as substrate for 
EpmA or its variant, whereas the (R)-enantiomer was activated and transferred to 
EF-P. This leads to the conclusion that alterations at the C3 stereocenter and 
concurrent absence of the terminal amino group were not tolerated by EpmA. 
Nevertheless, alteration of either the β- (6-AC) or the ε-amino group ((R)-3-AC) was 
tolerated, so both positively charged groups were recognized by EpmA. As 6-AC is 
only transferred by EpmA and not by its variant, contact of the ε-amino group from the 
substrate with amino acids in the catalytic pocket was not enough for conversion by 
EpmA_A298G.  
DAP and (R)-β-ornithine were the only compounds tested that were neither transferred 
nor activated by both of the ligases. DAP is a direct precursor of lysine in its synthesis 
pathway of most bacteria, leading from aspartate to DAP which is subsequently 
0 
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converted to lysine by the decarboxylase LysA [107]. However, the chemical 
composition of DAP differs from (R)-β-lysine in many ways, not least because of the 
large additional carboxyl group. The negative result for (R)-β-ornithine is not as 
obvious. Table 7 shows, that (R)-β-ornithine was neither activated by EpmA nor 
inhibiting the enzyme. Different concentrations of (R)-β-ornithine with and without 
additional (R)-β-lysine as competitor were tested for in vitro EF-P modification. The 
latter was analyzed by MS. At very high (R)-β-ornithine concentrations, EF-P was also 
not modified with (R)-β-ornithine by EpmA or EpmA_A298G, respectively, in vitro. 
When (R)-β-lysine was added to the reaction mixture, EF-P was fully modified by it, 
regardless of the (R)-β-ornithine concentration. 
Table 7: Concentration of (R)-β-ornithine and (R)-β-lysine in in vitro EF-P modification reaction. 
Mass shift due to modification of EF-P was detected by MS analysis.   
 EpmA_A298G EpmA 
(R)-β-ornithine 500 mM 10 mM 500 mM - 5 mM 10 mM 20 mM 
(R)-β-lysine - - 10 mM 
Δmeasured 1.1 1.1 1.1 128.2 129.2 128.2 129.2 
Nevertheless, this result is in line with literature as it is known that tRNALys is 
mischarged by LysRS with non-cognate substrates like arginine, threonine, 
methionine, leucine, alanine, serine and cysteine, but interestingly not with ornithine in 
vitro [54]. Jakubowski et al. suggested an efficient editing mechanism including 
cyclization of ornithyl adenylate. Here, the δ-amino group attacks the activated 
carbonyl group to yield AMP and ornithine lactam (3-aminopiperidin-2-one), which 
exhibits a quite stable 6-atom ring [54]. Having this in mind, it is conclusive that despite 
high relatedness of (R)-β-lysine and (R)-β-ornithine, the latter is not activated by EpmA.  
 
Figure 26: Hypothetical mechanism of lactam formation of activated ornithine. (A) For the 
unnatural LysRS substrate (S)-α-ornithine Jakubowski et al. postulated a ring formation that 
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prevents it from transfer to tRNA [54]. (B) The hypothetical pathway can be transferred to (R)-β-
ornithine. 
Taken together, eight of the 13 tested substances were transferred to EF-P by at least 
one of the enzyme variants in the in vitro approach. As all the substrates which could 
be activated were subsequently transferred to EF-P it can be concluded that the first 
substep is the bottleneck of EpmA catalysis and pre-transfer editing is performed.  
3.3.3.4 Performance of synthetically modified EF-Ps in in vitro translation 
Having created seven synthetically modified EF-Ps the question arises whether they 
perform equally well as (R)-β-lysylated EF-P at the ribosome. They all exhibit the 
elongated tip of EF-P at K34, but it is questionable if orientation and charge conditions 
enable optimal interplay with the PTC of the ribosome.  
To test whether the novel PTMs can support EF-P mediated rescue of polyproline-
stalled ribosomes an in vitro transcription/translation system reconstituted from purified 
components (PURExpress, NEB Biolabs) was set up. As readout for translation 
efficiency NanoLuc luciferase (NLuc), a small protein (19.1 kDa) that can convert 
furimazine into furimamide and thereby emits light, was used. Naturally, the enzyme 
lacks any diproline motif. Accordingly, nluc ORF was extended 5’ by a short codon 
motif encoding RPAP as control or RPPP to cause a translational arrest being 
alleviated by modified EF-P (Figure 27AB) [16]. Hence, the more efficient ribosome 
rescue is, the faster Nluc is translated and the more light is produced in a time-
dependent manner (Figure 27B). Figure 27C shows the bar graph of RPPP-nluc 
expression after 30 min. In vitro transcription/translation reaction was accelerated 4.5-
fold when (R)-β-lysylated EF-P instead of unmodified EF-P was added to the reaction 
mixture. This result was also confirmed by Ude et al. who found a similar ratio [16]. By 
contrast, none of the EF-P variants charged with a non-cognate substrate reached a 
translational speed which was equal or higher than observed for EF-PRβlys. In this 
context it was not decisive if the modification has been attached in vitro or in vivo as 
there was no statistically significant difference in nluc expression (Figure 27C).  
EF-P modified with (R)-β-lysine was superior to all tested non-cognate substrates so 
only this EF-P optimally performed at the ribosome in the context of EF-P orientation 
and charge conditions at the elongated tip of EF-P at K34.  
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Figure 27: In vitro transcription/translation efficiency of RPPP-Nluc using synthetically modified 
EF-Ps. (A) Schematic depiction of the cell-free transcription/translation experiment with either a 
RPAP or a RPPP motif upstream of nluc. The latter requires functional EF-P for robust translation 
of NanoLuc Luciferase. Consequently, functionality of the in vitro modified EF-Ps can be 
detected by luminescence readout. (B) Time course of RPAP-nluc and RPPP-nluc expression 
with either no, unmodified or in vivo modified EF-P over 30 min. RPPP-nluc expression was 
impeded in the presence of no or unmodified EF-P. One exemplary replicate is shown. (C) Bar 
graph of RPPP-nluc expression after 30 min. Successfully in vitro modified EF-Ps (verified by 
IEF or MS analysis), unmodified EF-P (negative control) and in vivo modified EF-P (positive 
control, EF-PRβlys) were subjected to in vitro transcription/translation assay. RPPP-Nluc 
translation efficiencies were determined for at least three independent samples. Only EF-P 
modified in vitro (blue) or in vivo (light grey) with (R)-β-lysine exhibited significantly higher nluc 
expression than when unmodified EF-P (grey dashed line) was added to the reaction mixture. 
Results of the two-tailed t-test are indicated **: p < 0.01, ***: p < 0.001.  
Reportedly, the ε-amino group of the protruding EF-P lysine gets acetylated in vivo 
when the modification system is missing [36]. This is proven for EF-P of B. subtilis, but 
lysine acetylation is a widespread PTM [108]. Consequently, this protein variant was 
included in the study. Chemical biology provides the possibility to obtain a post-
translationally modified protein when the corresponding transfer enzyme is unknown 
or difficult to prepare. Therefore, acetylated EF-P was generated utilizing the 
AcKRS/tRNAPyl dependent amber suppression system described by Volkwein et al. 
[66]. Here, efp was mutated with a nonsense mutation TAG at position 34. Upon 
suppression with acetyllysine utilizing the aaRS/tRNA pair AcKRS/tRNAPyl the EF-P 
variant bearing an acetyl group at K34 was produced (EF-PAcK) and successful 
expression confirmed by vertical IEF (Figure 28A). Nevertheless, this variant did not 
result in better in vitro transcription/translation efficiency than it is the case for EF-P in 
the unmodified form (Figure 28B). 
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Figure 28: EF-P modified with acetyllysine 34. (A) EF-P was produced with acetyllysine at 
position 34 using amber suppression [66]. (B) In vitro transcription translation of RPPP-Nluc is 
not stimulated by EF-P with acetyllysine at position 34.  
In conclusion, translation of proteins containing a triproline motif was not stimulated by 
synthetically modified EF-Ps and thereby showed the exceptional achievement of (R)-
β-lysylated EF-P during translation explaining its evolutionary selection.   
3.3.4 Unnatural EF-P modification in vivo   
Undoubtedly, promiscuity of EpmA towards its donor substrate was shown. Using the 
natural enzyme EpmA, EF-P was diversely modified in the presence of lysine 
derivatives. As B. subtilis it is known to exhibit an incomplete modification status (5-
aminopentanol, hydroxypentanone, pentanone attachment [36]), I aimed to elucidate 
the modification status of E. coli EF-P in vivo when epmB was deleted. As there is no 
metabolic pathway known to circumvent epmB deletion, the canonical donor substrate 
of EpmA was missing and it was questionable, if EpmA transfers other substrates in 
vivo.  
First, functionality of EF-P in E. coli ΔepmB was tested using a system described by 
Ude et al. [16]. Truncated cadC was fused to a triproline motif and lacZ and 
subsequently introduced to a plasmid backbone (Figure 29A). EF-P in its functional 
form was necessary to result in lacZ expression that could be detected by β-
galactosidase activity and quantified in Miller Units. E. coli WT, epmA and epmB 
deletion strains were transformed with this PPP-lacZ containing plasmid and their β-
galactosidase activities compared in Figure 29B (white bars). Irrespective which of the 
EF-P modification systems was deleted, ΔepmA and ΔepmB showed similar 
phenotypes with a drastic reduction of β-galactosidase activity compared to WT. 
Overproduction of EpmA or EpmA_A298G in E. coli ΔepmB (blue frame) showed no 
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significant increase in β-galactosidase activity indicating inactivity of EF-P in these 
cases. Complementations of the deletion phenotypes by epmA or epmB expression 
from an integrated plasmid were successful and interestingly also epmA_A298G 
complements ΔepmA phenotype.  
As EF-P is unfunctional in E. coli ΔepmB – irrespective of plasmid-encoded epmA or 
epmA_A298G addition to assist transfer of non-cognate substrates based on their 
substrate promiscuities – the question arises whether addition of different lysine 
analogs can lead to uptake, activation, transfer and finally functionality of EF-P in vivo 
(Figure 29 strategy 1, blue).   
β-galactosidase activity was repeated with E. coli ΔepmB transformed with the PPP-
lacZ plasmid and a plasmid containing epmA, epmA_A298G or none of these (framed 
blue in Figure 29B). This time, LB medium was supplemented with one of the 11 lysine 
derivatives in a concentration of 10 mM, if not otherwise mentioned. This concentration 
was chosen because Km values depicted in Table 5 are in the low millimolar range and 
because it is much higher than the intracellular lysine derivative concentrations, which 
are e. g. 0.4 mM for (S)-α-lysine and 0.01 mM for (S)-α-ornithine [92]. Therefore, E. coli 
ΔepmB unable to produce (R)-β-lysine was used to check whether supplementation 
with lysine derivatives helps to overcome the ΔepmB phenotype by modifying EF-P 
with a non-cognate substrate in vivo. 
Figure 29C shows the bar graphs for each of the possible substrates at natural EpmA 
production levels (plain bar) and - to provoke substrate promiscuity of EpmA - for 
subsequent overproduction of EpmA (dotted bar) and EpmA_A298G (squared bar), 
respectively.  
Supplementation with (R)-β-lysine led to a 9 - 12 times higher β-galactosidase activity 
than in LB without additional substrate, on the one hand indicating the improvement of 
translation by successfully post-translationally modified EF-P, but on the other hand 
also indicating promiscuity of E. coli amino acid transport systems. From all other 
tested substrates, the enantiomer (S)-β-lysine was the only one which detectably 
improved EF-P compared to EF-Punmod. Here it is assumed that the magnification factor 
of 1.2 - 1.4 could be enhanced by higher (S)-β-lysine concentration in the medium (> 
0.25 mM).  
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Figure 29: Translation of PPP-LacZ in E. coli BW25113 WT, ΔepmA and ΔepmB. (A) Schematic 
depiction of the EF-P-dependent in vivo reporter assay. A triproline translation motif (RPPP) 
requires functional EF-P for robust translation of truncated CadC linked to LacZ, whose 
translation was detected as β-galactosidase activity [16]. All strains mentioned in this figure were 
transformed with the described plasmid. (B) β-galactosidase activity in E. coli WT, ΔepmA and 
ΔepmB. Introduction of a second plasmid (-: empty vector) enables expression of either epmA, 
epmA_A298G or epmB. Complementation of the deletion phenotypes was successful, cross-
complementation of ΔepmB phenotype was not. Here, overexpression of epmA or epmA_A298G 
was not sufficient to convert EF-P into the functional state. At least three independent samples 
were measured. Error bars indicate s.e.m.. (C) β-galactosidase activity in E. coli ΔepmB grown 
in LB medium supplemented with different lysine derivatives at a concentration of 10 mM. 
Irrespective of additional expression of epmA (dotted bars) or epmA_A298G (squared bars), EF-P 
modified with (R)-β-lysine in vivo exhibited superior efficiency of protein translation. The 
concentration of (S)-β-lysine was ~0.25 mM. (R)-3-AC was supplemented in a concentration of 
1 mM due to growth defects at higher concentrations. At least five independent samples were 
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measured. Results of the two-tailed t-test are indicated as following ***: p < 0.001, *: p < 0.05. (D) 
Schematic depiction of purification strategy of endogenous EF-P. (E) Vertical IEF of natively 
purified EF-P from WT control and E. coli ΔepmB with subsequent overexpression of epmA and 
epmA_A298G. Two bands, corresponding to unmodified and modified EF-P, were found in E. coli 
ΔepmB overexpressing epmA. EF-P was even completely in the modified state when 
epmA_A298G was overexpressed. This indicates an attached but non-functional non-cognate 
PTM of EF-P in vivo. (F) MS spectra of the samples framed in red. (E) Fragmentation spectra of 
the EF-P peptide containing the critical K34 is shown to be modified with a lysine residue. The 
MS spectra were searched for all other tested modifications without positive result. This 
confirms that lysylation is indeed the endogenously occurring modification of EF-P in E. coli 
ΔepmB overproducing EpmA_A298G.  
Despite the fact that Km for (R)-β-lysine is magnitudes higher than for (S)-α-lysine 
regarding EpmA_A298G in vitro, β-galactosidase activity in vivo of the first-mentioned 
substrate was enhanced by a factor of 13 compared to (S)-α-lysine (Figure 29C). This 
fact indicates that in E. coli ΔepmA complemented with EpmA_A298G, EF-P is 
modified with (R)-β-lysine instead of the high affinity substrate (S)-α-lysine, even 
though intracellular concentration of (R)-β-lysine is likely to be low compared to (S)-α-
lysine. When (R)-β-lysine pathway was deleted, EpmA_A298G attached its high affinity 
substrate (S)-α-lysine to EF-P. (R)-β-lysine supplementation of LB complex medium 
presumably leads to complete modification with (R)-β-lysine because otherwise 
ΔepmA phenotype could only be restored partially by complementation with 
EpmA_A298G.  
As second strategy to elucidate unnatural EF-P modifications in vivo, endogenous 
EF-P from E. coli ΔepmB was natively purified and subjected to IEF and MS analysis 
(Figure 29D-F). The purification protocol for endogenous EF-P includes anion 
exchange chromatography and gel filtration to yield untagged, natively modified EF-P. 
By this rapid and convenient method EF-P from the WT control and E. coli ΔepmB 
transformed with an inducible plasmid for overexpression of EpmA or EpmA_A298G 
was isolated (Figure 29B, red frames). The three indicated samples were subjected to 
vertical IEF followed by Anti-EF-PE.c. Western Blotting to verify abundance of EF-P and 
to elucidate the modification status. Figure 29E nicely shows complete modification in 
the WT strain as positive control but interestingly also clear bands at the same height 
than the modified EF-P control band for both E. coli ΔepmB samples. This suggests a 
modification with additional positive charge compared to K34 like it is the case for a 
PTM with two amino groups. In addition, a band at the height of unmodified EF-P was 
visible when EpmA was overproduced. The samples were subjected to chymotrypsin 
digest and LC-MS/MS analysis and it was found that indeed, overproduction of 
EpmA_A298G in E. coli ΔepmB led to a modification at K34 at the loop of EF-P (peptide 
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PGKG, Figure 29F). This modification with the mass of 129.19 Da potentially originated 
from (S)-α-lysine. In the present study, the aim was to find unnatural EF-P 
modifications in vivo. As result the lysylation of EF-P was detected when 
EpmA_A298G was overproduced although epmB was deleted in E. coli. 
3.4  Modification of EF-P in B. subtilis and other Firmicutes 
3.4.1 Modification status of EF-PB.s. during different growth phases 
In contrast to EpmA which establishes (R)-β-lysylation in a single step, the PTM of 
B. subtilis EF-P seems to be developed in a yet unsolved multi-step process. Here, a 
precursor is attached to EF-P at an early stage of the modification pathway that is then 
subject to ongoing development in the bound form. The complex pathway is postulated 
to include at least four different enzymes [36]. This may lead to a situation contrary to 
E. coli, where EpmA and EF-P were balanced in all growth phases to ensure full PTM. 
To elucidate the ratio of unmodified-to-modified EF-P at different growth phases, cells 
were collected at eight time points and lysed. Application of the same procedure as 
described for E. coli EF-P was unsuccessful because bands on the IEF gels were 
invisible or not pleasantly resolved (not shown). Therefore, an additional protein 
precipitation step with TCA/acetone was included and the IEF gel was rehydrated in 
presence of urea/thiourea to increase their solubility in general and to avoid 
aggregation of proteins at their pIs. Urea is a solubilizing agent that prevents hydrogen 
bonds and consequently, unwanted protein aggregation formation that affects mobility 
in a negative way and impedes sharp band resolution [109]. Additional thiourea 
ensured denaturation by cleavage of disulfide bridges. As some proteins require 
detergent solubilization, the zwitterionic detergent CHAPS (3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate) was used.  
Figure 30 shows that during all growth phases of B. subtilis, two distinct EF-P bands 
are visible, one at the height of the control (EF-Punmod) and one that is shifted towards 
the cathode of the gel, indicating an additional positively charged group. Proportion of 
EF-Pmod is predominant during all phases although it seems to decrease over time. 
Witzky et al. found that 5-aminopentanol, hydroxypentanone and pentanone are 
attached to K32 of EF-P in WT cells [36]. Out of these three compounds, only 5-
aminopentanol exhibits the positively charged group detected by IEF analysis shown 
in Figure 30.  
Consequently, the majority of EF-P is 5-aminopentanolated during all growth phases. 
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Figure 30: Denaturating horizontal IEF reveals modification status of B. subtilis EF-P during 
different growth phases. LP: lag phase, EE/ME/LE: early/middle/late exponential phase, SP: 
stationary phase. (A) Eight time points of the growth curve were chosen (highlighted in red) and 
cell lysates were subjected to protein precipitation. (B) Denaturating horizontal IEF (20 – 100 µg 
total protein per lane). Western Blot analysis using Anti-EF-PB.s. shows two EF-P variants (ratio 
indicated at the right) with distinct pI values corresponding to unmodified and modified EF-P. 
n. d.: ratio EF-P modified-to-unmodified not estimable.  
3.4.2 Aminotransferases potentially involved in the post-translational 
modification of EF-PB.s. 
The PTM of B. subtilis EF-P develops in EF-P bound form to finally yield 5-
aminopentanolated EF-P. It appears likely that one reaction step is catalyzed by an 
aminotransferase (transaminase) which donates the amino group. 13 described or 
postulated aminotransferases were chosen, and their corresponding deletion strains 
analyzed regarding behavior of their EF-Ps in a pH gradient by denaturating horizontal 
IEF. Results are shown in Figure 31 (bottom). Here, especially GsaB, EpsN and IlvK 
seem to be interesting candidates for further study because a band at the height of 
unmodified EF-P was found and WT band was absent.  
It was reported that deletion of efp in B. subtilis leads to impaired swarming motility 
that is caused by a negative impact on flagellar biosynthesis [110]. Swarming is 
differentiated from swimming by participation of a surface and increased involvement 
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of flagella. Therefore, also swarming behavior of the 13 aminotransferase deletion 
strains was analyzed.  
In Figure 31, the 13 aminotransferase deletion strains are shown to exhibit distinct 
swarming abilities. Here, especially B. subtilis ΔyhdR, Δdat and ΔyaaO exhibit similar 
low swarming diameters compared to B. subtilis Δefp. 
 
 
Figure 31: 13 aminotransferase deletion mutants are subjected to swarming assay and analyzed 
regarding their modification status. Swarming behavior of the aminotransferase mutants are 
compared to B. subtilis Δefp to elucidate potential enzymes involved in EF-P PTM pathway. Red 
crosses highlight the aminotransferase mutants which exhibit a swarming deficiency, or which 
contain EF-P in the unmodified state.  
Characterization of 13 aminotransferase deletion strains of B. subtilis regarding their 
EF-P modification status and their swarming phenotypes suggested three candidates 
each, potentially involved in PTM of EF-P. To resolve whether these effects are direct 
or indirect more research is required in the future.  
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4 Discussion 
4.1 Unnatural post-translational modifications of EF-P  
In this study it was shown that EF-P in E. coli ΔepmB is unfunctional but not necessarily 
unmodified. This contradicts the commonly accepted opinion, that deletion of epmA or 
epmB in E. coli leads to completely unmodified EF-P and that these cells phenocopy 
Δefp strains. When endogenous EF-P was purified from a strain overproducing EpmA 
or EpmA_A298G, vertical IEF unexpectedly revealed a band at similar height to 
modified EF-P. Expression of the WT ligase led to similar amounts of unmodified and 
modified EF-P, whereby expression of epmA_A298G exhibited complete modification 
with a non-cognate EpmA substrate. MS revealed that EF-P was modified with a PTM 
of 129.19 Da at β3/β4 loop which corresponds to lysylation. β-lysine is neither known 
to be abundant in the (S)- (no pathway known) nor the (R)-configuration (known 
pathway deleted). With a concentration of 0.4 mM (S)-α-lysine is a highly abundant 
metabolite in the cell, whereas the nonproteinogenic amino acid (R)-α-lysine is not [92]. 
In addition, the catalytic pocket of EpmA_A298G is optimized for (S)-α-lysine. 
Therefore, it is concluded that (S)-α-lysine is the non-cognate PTM of EF-P in E. coli 
ΔepmB (Figure 32AC).  
 
Figure 32: Endogenous modification of EF-P in E. coli (A, B) and E. coli ΔepmB (C, D). (A, C) 
Schematic pathway of post-translational modification with or without conversion of (S)-α-lysine 
by EpmB. (B, D) Structural insights into the translation of a polyproline motif. Interaction of 
modified EF-P with the CCA end of the P-site tRNA and 23S rRNA as determined by Cryo-EM 
[14]. If (R)-β-lysine is absent due to deletion of epmB, EF-P is nevertheless post-translationally 
modified by EpmA(_A298G). Then, (S)-α-lysine is attached. Fewer contacts with the ribosome 
are possible for EF-PSαlys, EF-P is unfunctional during polyproline translation.  
Unnoticed by investigators, Peil et al. found 2 % modified EF-P (mass shift +128 Da) 
in E. coli ΔepmB [33]. In this thesis, 64 % modification at subsequent epmA 
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overexpression and complete modification of EF-P at epmA_A298G overexpression 
was detected. One might claim that deletion of epmB does not resemble an inherently 
occurring situation in E. coli. But Schmidt et al. could not detect EpmB in every cell of 
E. coli, grown in LB medium to stationary phase. 78 % (after 1 day) and 97 % (after 3 
days) of cells exhibit no EpmB copy at all, indicating at least low abundance of the 
protein [1]. 
Cryo-EM structures of a ribosome stalled at a polyproline motif either with or without 
EF-PE.c. revealed lability of the P-site tRNAPro in the latter case [14]. EF-P interacts with 
tRNAPro via Y183 and with the 30S subunit via R186. Domain III of EF-P (G144, D145, 
T146) interacts with the mRNA and ribosomal protein S7. Moreover, (R)-β-
lysylhydroxylysine enables additional interaction: First, the hydroxy group at C4 of K34 
forms hydrogen bonds with the first cytosin of the CCA end of P-site tRNAPro. Second, 
the terminal amino group at C6 of the (R)-β-lysyl residue is in proximity to the 
phosphate backbone of CCA (Figure 32B). Third, both the carbonyl group at C1 and 
the amino group at C3 of (R)-β-lysine form hydrogen interactions with the ribosome 
(A2439). The last-mentioned interaction is missing in EF-PSαlys (Figure 32D) and the 
modified EF-P is unfunctional in rescue of polyproline stalled ribosomes. This indicates 
the stabilizing effect on the CCA end of P-site tRNAPro through various interactions of 
EF-PRβlys, which enables its optimal positioning for peptide bond formation between 
prolines [14]. 
The described mischarging of EF-P with (S)-α-lysine in vivo, mediated by 
EpmA(_A298G) and found in E. coli ΔepmB leads to modified but unfunctional EF-P. 
This does not seem to be advantageous at first sight, but recent research identified 
states in which reliance on functional EF-P is low and here, non-cognate modification 
may not be disadvantageous. Tollerson et al. reported recently, that ΔepmA, ΔepmB 
and Δefp phenotypes (like slow growth, increased antibiotic sensitivity, loss of 
virulence [111–114]) are dependent on the growth state, indicating demand on 
functional EF-P especially in high growth rate conditions. Interestingly, reduction of 
temperature for E. coli growth leads to clear reduction of the Δefp phenotype in many 
ways (polyproline translation, polysome ratios, antibiotics susceptibility). This matches 
the findings of Klee et al. who compared the growth behavior of plant pathogen 
E. amylovora WT and ΔepmB strain [113]. Remarkably, they found a growth defect 
only in LB rich medium (pH 7.0) whereas in minimal medium (M9, pH 7.0) both strains 
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grew comparably well [113]. Apparently, EF-P reliance is not only caused by 
abundance of XPPX motifs but also influenced or even regulated by external stimuli or 
conditions. Putatively, EF-P is modified with (S)-α-lysine in these informal EF-P states, 
meaning states where EF-P in the unfunctional form is tolerated, such as in slow 
growth states (e. g. 25 °C), when disadvantageous Shine-Dalgarno sequences are 
present or unfavorable start codons are chosen. In all these cases dependence on 
functional EF-P is low due to reduced protein translation need or low translation 
initiation rates that prevent ribosome queuing in general [112]. Therefore, the non-
cognate EpmA mediated lysylation of EF-P potentially resembles EF-P status in growth 
phases of low EpmB copy number or in states where reliance on functional EF-P is 
negligible.  
An interesting way of decreasing dependency on functional EF-P is reported in 
E. amylovora. In a recent study a suppression strategy of efp, epmA and epmB deletion 
phenotypes is proposed [90]. Here, colony size as well as virulence was restored in 
these deletion mutants by additional hrpA3 deactivation or deletion [90]. HrpA3 is a 
DEAH family RNA helicase-like protein with predicted ATP-dependent RNA helicase 
function but its mode of action remains unclear. In E. coli HrpA3 is associated with the 
degradosome [115] so it can be speculated that hrpA3 deletion leads to a delay in 
mRNA degradation at stalled ribosomes and thereby provides a larger time window for 
translation processes [90].  
Consequently, the question was addressed which substrate EpmA_A298G prefers to 
transfer to EF-P in vivo when (R)-β-lysine and (S)-α-lysine are present (E. coli ΔepmA). 
The first mentioned substrate was supplemented to LB medium in a concentration of 
10 mM, whereby the intracellular concentration of (S)-α-lysine was determined 
elsewhere to be 0.4 mM [92]. The phenotype of E. coli ΔepmA was complemented 
(87 % compared to WT) by overexpression of epmA_A298G when the translation level 
of PPP-LacZ was examined. As (S)-α-lysylated EF-P was shown to be unfunctional in 
rescue of polyproline stalled ribosomes, the phenotype is complemented by preference 
of (R)-β-lysine over the low Km substrate of EpmA_A298G. Apparently, assurance of 
EF-P functionality is number one priority.The research shown in this thesis expands 
our understanding and sensitizes for the differentiation between deleted, unmodified, 
unnaturally modified and modified functional EF-P. 
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In line with expectations, EF-P is not functional in E. coli ΔepmB and therefore 
translation of PPP-LacZ was drastically reduced compared to WT. This finding is also 
not altered by overexpression of epmA(_A298G) to facilitate modification of EF-P in 
this (R)-β-lysine pathway deletion strain. Weakening of the deletion phenotype was 
tested by addition of 11 different lysine derivatives to the cultivation medium and only 
successful using the cognate EpmA substrate and its enantiomer (S)-β-lysine, whereas 
other (R)-β-lysine like compounds supplemented to the medium had no effect. 
Nevertheless, results show that lysine derivatives were successfully transported into 
the cell. It cannot be excluded that different uptake abilities affect intracellular lysine 
derivative concentrations and thereby indirectly manipulate EF-P modification 
efficiency. Two lysine transport systems are characterized in E. coli: the lysine-
arginine-ornithine (LAO) system [HisQ][HisP]2[HisM][ArgT] and the lysine-specific 
permease (LysP) [116]. As E. coli amino acid transport is proven for α-lysine and 
ornithine and indicated for (R)-β-lysine, it is likely that the other tested substances were 
also transported. This assumption was also corroborated by similar growth behaviors 
(not shown). (R)-3-AC provided a notable exception because a reduction of the LB 
supplementation from 10 mM to 1 mM was necessary to enable growth. As 
concentration-dependent inhibition of EpmA(_A298G) was induced by (R)-3-AC in vitro 
it might be possible that this compound also inhibited other enzymes of E. coli leading 
to this severe growth defect at concentrations higher than 2 mM. 
Having documented that EpmA unnaturally post-translationally modifies EF-P with (S)-
α-lysine and - when added to the medium - also with (S)-β-lysine in vivo, further 
substrates were found that were attached to EF-P in vitro. EpmA forms the adenylate 
of its cognate substrate (R)-β-lysine and of five non-cognate substrates but excludes 
in vitro activation of four other tested lysine derivatives. This shows that not all chemical 
groups of (R)-β-lysine are equally important for recognition, binding and activation by 
EpmA. Only lysine derivatives with 6-atom carbon chains were activated by EpmA (no 
activation of ornithines), whereby the ε-terminus was tolerated to be free of chemical 
groups ((R)-3-AC) or to exhibit an amino group, but not to be bulky (DAP). Moreover, 
an amino group is required either at ε- (6-AC), β- ((R)-β-lysine, (R)-3-AC) or α- ((R/S)-
α-lysine, 5-hydroxy-(S)-α-lysine) position which enables interaction with amino acid 
residues of the catalytic pocket of EpmA.  
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Beside these configurational requirements, stereochemical demands were elucidated 
by the fact that Km value increases drastically by a factor of ~40 when (S)-β-lysine is 
compared to (R)-β-lysine as substrate. Even more severe, EpmA selectively activated 
(R)- but not (S)-3-AC. The biochemical characterization of EpmA revealed the negative 
effect of an additional hydroxy group, nevertheless, 5-hydroxy-(S)-α-lysine was also 
activated by EpmA. 
Backmutation of EpmA’s catalytic pocket to resemble its evolutionary origin LysRS 
deepened the understanding of the interplay between amino acid residues of the 
catalytic pocket and the donor substrate ligand. The anticipated preference for (S)-α-
lysine was achieved, moreover EpmA_A298G explicitly preferred substrates with α-
amino groups ((R/S)-α-lysine, (S)-α-ornithine, 5-hydroxy-(S)-α-lysine) which 
manifested in lower Km values towards all these substrates compared to WT EpmA. 
EpmA_A298G requires an α- or β-amino group at its substrate. 6-AC, which exhibits 
just an ε-amino group, was not activated by the variant. Also here, hydroxylation of the 
substrate was detrimental which is shown by increase of the Km value by a factor of 
100 when comparing (S)-α-lysine with its 5-hydroxylated version. The Km value 
towards (S)-α-lysine decreased by a factor of 80 compared to EpmA. At the same time 
and in line with expectations the Km towards (R)-β-lysine increased by a factor of 60. 
This is a finding that contradicts Roy et al. who found similar Km values towards (R)-β-
lysine for both enzyme variants [32]. Notably, this study provides a much more detailed 
and completive substrate spectrum analysis than found in [32] and demonstrates 
EpmA(_A298G)’s pronounced donor substrate promiscuity.  
The hypothesis that enzyme promiscuity especially allows for innovative enzyme 
functions is supported by ancestral sequence reconstructions that find ancestral 
enzyme forms to exhibit broader substrate specificities [117]. Beside considering a 
promiscuous enzymatic activity as starting point for the evolution of a new enzyme it 
can also be employed by protein engineers and synthetic biologists. Urgent problems 
of our time are tackled like bio-based instead of petroleum-based manufacturing (e. g. 
vanillin production [118]) or degradation of anthropogenic pollutants [119]. Enzyme 
promiscuity is also used in chemical industry, naming just one example from BASF, 
where Burkholderia plantarii lipase is used to produce enantiopure (R)-
phenylethylamine, a platform chemical for production of pharmaceuticals and 
pesticides [120]. Here, individual industrial applications or even the creation of novel 
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metabolic pathways are conceived on the base of promiscuous enzymes which are 
optimized during directed evolution approaches [52]. High-throughput approaches 
identified promiscuous enzymes that stood in for essential proteins or gave rise to 
resistance against antibiotics or toxins [52]. Therefore, it becomes clear why Copley et 
al. designated promiscuity as the fuel of evolutionary innovation [52]. Not least it forms 
the basis of EF-P modification with non-cognate substrates demonstrated in this thesis. 
All amino acid derivatives which were activated by EpmA were also transferred to EF-P 
which implies that the first substep is the bottleneck of the reaction and determines the 
expanse of promiscuity. It is also clarified that pre-transfer editing is observed, and 
post-transfer editing is absent. (S)-3-AC, DAP and (R)-β-ornithine were not activated 
by EpmA in vitro to form the adenylate and also not attached to EF-P in vitro. In 
contrast, the artificial modification of EF-P was successfully performed by 
EpmA(_A298G) in vitro to create EF-PE.c. modified with (S)-β-lysine, (R/S)-α-lysine, 
(S)-α-ornithine, 5-hydroxy-(S)-α-lysine, (R)-3-AC or 6-AC (Figure 33A). It must be 
noted that modification of EF-P was incomplete (EF-Punmod present) in the case of 5-
hydroxy-(S)-α-lysine attached by EpmA as well as (R)-α-lysine and (S)-α-ornithine 
attached by EpmA_A298G. As Km values for these combinations are high, incubation 
with higher concentrations of the non-cognate substrate potentially leads to complete 
modification.  
In conclusion, the variety of known natural PTMs of EF-P (and its homologs a/eIF5A) 
which all elongate the tip between β-strands 3 and 4 by addition of (R)-β-lysine, 
rhamnose, 5-aminopentanol or by formation of hypusine (eukaryotes, archaea) was 
expanded by seven synthetic PTMs using EpmA(_A298G). Nevertheless, these EF-Ps 
were shown to be unfunctional in the rescue of polyproline stalled ribosomes in vitro. 
It was made use of the commercially available kit for cell-free synthetic biology (CFSB), 
the PURE system. Apparently, the elongated tip of EF-P at K34 does not exhibit the 
correct orientation or charge condition to enable optimal interplay with the PTC of the 
ribosome. Instead, modification of EF-P by (R)-β-lysine in vivo or in vitro is superior to 
all synthetically modified variants of EF-P which explains its evolutionary selection.  
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Figure 33: Overview of natural and synthetic lysine modifications. (A) Synthetic post-
translational modifications of EF-P. The indicated lysine derivatives were activated and 
transferred by EpmA or EpmA_A298G. (B) Lysine modifications successfully introduced using 
the amber suppression system. Results are partially derived from [121]. (C) Lysine PTMs in 
E. coli according to PLMD database. The ε-terminal lysine modifiers are grouped and 
schematically depicted. The number behind the modification corresponds to the number of 
proteins modified by that compound in E. coli. The figure is derived from [122]. 
Interestingly, EF-P modified with enantiomer (S)-β-lysine exhibits different behavior in 
vitro and in vivo. Using the PURE system, no stimulating effect on PPP-Nluc translation 
was observed. In contrast, addition of (S)-β-lysine to E. coli ΔepmB growing in LB 
medium led to significantly increased translation of PPP-LacZ compared to 
unsupplemented medium. Thereby, (S)-β-lysine is either the only non-cognate 
substrate in this study leading to functional EF-P when attached to K34 or a yet 
unknown enzyme partially converts (S)-β-lysine into (R)-β-lysine in E. coli. The 
compound naturally occurs in the (S)-α-lysine degradation via acetate pathway which 
is catalyzed by L-lysine 2,3-aminomutase KamA (PDB: 2A5H [123]) in organisms like 
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Clostridium subterminale or B. subtilis [124, 125]. While KamA and EpmB share the 
same substrate and both produce one specific enantiomer of β-lysine, the two 
enzymes vastly differ in activity. The turnover number of E. coli EpmB is 5.0 min-1 
which indicates its low activity and leads to the conclusion that (R)-β-lysine is produced 
in small amounts [42]. Apparently, low intracellular concentration of this specialized 
molecule is enough to be accepted by the cytosolic protein EpmA and to maintain 
adequate EF-P modification. In contrast to that, KamA takes over an important role in 
lysine metabolism, explaining its high activity. 
EF-P was shown not to be modified with (S)-glutamine and (S)-arginine by 
EpmA(_A298G) in vitro, although it is reported that tRNALys is mischarged by LysRS 
with non-cognate amino acids including arginine [54]. The biochemical characterization 
revealed that bulky terminal groups impede activation (like it is the case in DAP and 
(S)-arginine) and carbon chain shortening (like in ornithine and (S)-glutamine) 
compared to lysine is not tolerated, so exclusion of the two amino acids is explainable. 
Compounds like this need to be tackled with a different strategy, namely the amber 
suppression system utilizing PylRS and its variant AcKRS (Figure 33B). It is used for 
bulky residues and here, different carbon chain lengths are tolerated. Therefore, the 
amber suppression strategy complements the described use of the inherent substrate 
promiscuity of EpmA to synthetically modify EF-P in vitro (Figure 33A). This reported 
strategy is suitable for close (R)-β-lysine analogs. Synergy of both approaches not only 
yields a pool of unnatural lysine modifications on EF-P to study polyproline formation 
mechanism but also creates diverse potential applications for incorporation of 
noncanonic amino acids, β-amino acids and derivatizable groups into peptides. 
The amber suppression system manipulates protein structure and function by site-
specific incorporation of noncanonic amino acids. Derivatization of lysine at the ε-
terminal amino group is used to alter physical, chemical, or biological properties of the 
peptide and to enable incorporation of photocrosslinkers, fluorescent probes, spin 
labels, redox active groups, heavy atoms, and reactive groups [126]. To do so, an 
orthogonal aaRS/tRNA pair is used which does not interfere with the biosynthetic 
machinery of the host cell but recognizes the little used stop codon UAG (amber). 
PylRS, originating from Methanosarcina mazei, is an example of an aaRS showing 
untypically high substrate promiscuity. The PylRS/tRNAPyl set utilizes lysine derivatives 
which exhibit an ε-terminal carbonyl group and a hydrophobic, bulky moiety [126]. 
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Volkwein could show that this amber suppression system is suitable to introduce 2-
THF-, butyryl-, crotonyl-, propionyl-, and valeryllysine instead of K34 of EF-PE. c. when 
mutating the respective site to TAG [121]. Therefore, the tip of EF-P is successfully 
elongated in a PTM-independent, single translation step. Nevertheless, all these 
synthetic variants were unfunctional at polyproline stalled ribosomes. Also, (R)-β-
lysyllysine was not accepted as substrate by PylRS and therefore not incorporated into 
the nascent peptide chain so only a truncated variant of EF-P was observed. 
Promiscuity of PylRS together with its low selectivity towards the tRNAPyl anticodon 
offers the opportunity to easily engineer PylRS for applications in synthetic biology 
approaches [127]. Change of substrate specificity of PylRS towards (R)-β-lysyllysine 
and its close analogs is conceivable but intercepted by the new approach to use EpmA 
for synthetic EF-P modification.  
In this thesis, a variant of PylRS, acetyllysyl-tRNA-synthetase (AcKRS), enables 
incorporation of acetyllysine into proteins using the amber suppression system [66]. 
Lysine acetylation of proteins is a common and reversible PTM in eukaryotes and 
bacteria. Eukaryotic cells acetylate lysine residues enzymatically by lysine 
acetyltransferases (KATs) and lysine deacetylases (KDACs) or non-enzymatically with 
acetyl-CoA representing the acetyl donor [108]. The PTM specific antibody recognizing 
acetylated lysine enabled immunoprecipitation and in combination with high-resolution 
mass spectrometry-based proteomics identified 2,000 human proteins being 
acetylated at lysines and involved in all kinds of cellular processes, also in cancer 
progression. Several KATs, KDACs and acetyllysine recognizing proteins 
(bromodomain-containing proteins) are associated with cancer development and are 
targets of small molecules to provide potential cancer therapies [108]. In bacteria, most 
of the lysine acetylations are implemented non-enzymatically and mediated by acetyl 
phosphate. Therefore, this interesting lysine derivative was included into the study. For 
production of acetylated EF-P in vitro, Nε-acetyl-L-lysine was incorporate at amber 
codon position (TAG), which replaced the AAA codon coding for K34. The 
deacetylation reaction catalyzed by CobB was inhibited by addition of nicotinamide. 
Also this synthetically modified EF-P was found to be unfunctional in stimulation of 
PPP-Nluc translation.  
Independent of the strategy used – post-translational modification with EpmA or amber 
suppression – both aim for EF-P tip elongation and subsequently, a better 
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understanding of the structural mechanism of polyproline motif translation. Despite 
profitable structural insight by Cryo-EM structures, the detailed mechanism of peptide 
bond formation and the critical role of the distinct PTMs remain elusive. Deeper 
understanding of differently shaped PTMs fulfilling the same function at the ribosome 
is only possible by synthetic alteration of the conserved central residue of β3/β4 loop 
in EF-P. For example, (R)-β-lysylation, 5-aminopentanolation and hypusination have 
in common that the conserved lysine in β3/β4 loop is elongated by 4-6 carbon atoms, 
ending up in a terminal amino group in all cases. In contrast to that, the central moieties 
of the β3/β4 loop shown in Figure 33B do not contain a positively charged, terminal 
amino group. This underlines its critical role in stabilizing the P-site tRNA by interacting 
with the phosphate backbone of its CCA end.  
Due to the described preference of PylRS for bulky lysine derivatives, the PTM-
independent introduction of rhamnose via amber suppression should be tested in the 
future. This is especially interesting, as cross-complementation of EF-PE.c. with 
rhamnose, when an arginine residue at position 34 and EarP as modification enzyme 
are present, was published recently [38]. Here, it was reported that proline at the -2 
position compared to the conserved residue is favorable for lysylation and obstructive 
for rhamnosylation. Additional variation of the -2 proline to serine enabled EF-P 
functionality at the ribosome (at least when modified by EarP of S. oneidensis) leading 
to the conclusion that composition of the seven amino acids long β3/β4 loop of EF-P 
has direct influence on accessibility of the PTM enzyme as well as performance at the 
ribosome when stalling motifs are encountered. Further studies should take this into 
account no matter which approach is focused on, PTM-independent amber 
suppression or PTM-dependent modification via PTM enzymes. By that, further post-
translational modifications of lysine become accessible. Lysine is designated as 
hotspot for enzymatic and chemical PTMs. It is the most frequently modified amino 
acid and also the one with the widest range of different modifications [128].  
Lysine, arginine and histidine are the three basic amino acids encoded by the genetic 
code. Their positively charged groups at physiological pH positions these amino acids 
more frequently at the surface of proteins which makes the reactive group accessible 
for PTM [128]. The manifold PTMs of lysine are summarized in the ‘protein lysine 
modification database’ PLMD [129]. For example, EpmA is acetylated at K166, EpmC 
is acetylated at K28, EF-P is modified at five lysine residues with succinyl, acetyl or 
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hydroxyl groups. Among the 20 different lysine modifications are ubiquitin-like 
modifiers, the big group of acylations which result in amide-bound derivatives and 
others. For E. coli, the occuring lysine modifications and their abundance are 
summarized in Figure 33C. 
4.2 New insights into post-translational modification of EF-P in E. coli  
In this thesis, EF-P copy number was determined to be 7,360 per cell at stationary 
phase of an ON culture which agrees with previous research performed by Schmidt et 
al. who found 8,323 EF-Ps/cell [1]. Several growth conditions of E. coli were shown to 
exhibit higher copy numbers, naming just the exceptionally high value of ~35,000 
EF-Ps/cell in LB medium after 5 h of growth. This value is explainable by generally 
90 % higher protein biosynthesis rates during late exponential phase than during 
stationary phase [130]. 
Even more interesting than the exact copy number is the ratio of EF-P-to-EpmA and 
its impact on the degree of PTM. As expected, EF-P was completely in the unmodified 
state in E. coli ΔepmA and in the modified state when efp, epmA and epmB were 
overexpressed in parallel. Further variation of EF-P and EpmA copy numbers revealed 
that doubling of efp by introduction of a second chromosomal copy led to 50 % (R)-β-
lysylation of EF-P at endogenous EpmA levels, the rest remained unmodified. This 
important finding leads to two conclusions. On the one hand, excess of EpmA is 
avoided and it can be speculated that EpmA’s copy number is capped due to 
promiscuity of this enzyme and thereby prevents (S)-α-lysine modification of EF-P in 
vivo because this variant is unfunctional in polyproline rescue. On the other hand, the 
finding of 50 % PTM status suggests that translation of EpmA is not governed by EF-P-
mediated regulation. Instead, epmA and efp seem to be globally regulated. This is 
indicated by stable copy number ratios in E. coli at different growth conditions. Here, 
~550 EF-Ps per EpmA were measured at 21 conditions, whereby one outlier value 
pertains to slow growth conditions (chemostat, µ = 0.12) [1]. The stable copy number 
ratio between EF-P and EpmA becomes even more visible when the same 22 growth 
conditions are applied and EF-P-to-EpmB ratios are analyzed. Values vary between 
338 and 277,875.  
Now, numbers are added to the proposal established by Navarre et al. who suggested 
that low levels of epmA expression are satisfactory for high levels of function [111]. 
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The stable correlation of EF-P and EpmA is also expressed by the exhaustive PTM 
state of EF-P in vivo throughout all growth phases. 
Unbalancing these EpmA-to-EF-P levels could potentially affect pathogenicity, as it is 
known that PTMs play a role in fundamental metabolic reactions. Many cellular 
signaling states which are relevant for diseases are associated with higher modification 
status ratio [131]. Therefore, EpmA serves as potential target for intervention and 
piloting to alter the ratio of modification in clinically relevant strains. In vivo, the 
coordinated interplay between EpmA, EpmB and EpmC is necessary for functionality 
of EF-P and thereby indirectly for relief of polyproline stalled ribosomes and unimpaired 
protein synthesis. Two examples show that fast protein synthesis as response to 
changing environments is a requirement for the successful host invasion of pathogenic 
bacteria [9]. Therefore, EF-P exhibits relevance in possible future medical applications. 
The pathogen E. coli O157:H7 was shown to strongly rely on EF-P since this E. coli 
strain exhibits the highest number of PPX motifs. The zoonotic, facultative intracellular 
pathogen S. enterica was shown to be hypersusceptible to a variety of growth inhibitors 
(antibiotics, detergents, heavy metals) and exhibited attenuated virulence in mice due 
to changes in expression of pathogenicity island SPI-I proteins upon lack of functional 
EF-P [44, 46, 111].  
Unintendedly, the role of hydroxylation at the C4 atom of K34, catalyzed by EpmC, is 
further elucidated in this study. Chapter 3.2.1 shows that deletion of epmC led to 
unhydroxylated EF-P, as expected, but interestingly also 45 % of EF-P was in the 
unmodified state. Analysis of endogenous, immune-precipitated EF-P was reported to 
be 1.3 % modified but unhydroxylated (+129 Da), whereby the vast majority of EF-P 
exhibited the complete PTM (+144 Da) [33]. As hydroxylation as last step of the PTM 
pathway of EF-P is negligible for function [16, 20, 132] the stabilizing hydrogen bond 
interaction with the P-tRNA postulated by Peil et al. seems to be absent or of minor 
importance [14, 33]. Instead it can be speculated about a potential protective function 
of the hydroxyl group for the PTM as absence of the hydroxylation may facilitate 
cleavage of the lysylation of K34.   
Sir2-like deacetylase CobB was shown to unspecifically cleave amide bonds which link 
the lysine residue of a peptide to its PTM such as propionylation, succinylation, 
crotonylation, acetylation or modification with one of the 20 amino acids [129, 133, 
134]. Therefore, CobB was recently designated as general amidase in E. coli which 
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could be used to release unknown amide-bound lysine modifiers [134]. Wei et al. also 
demonstrated that neither the N-terminal amine-derived amide bonds nor peptide 
bonds within the protein backbone were altered [129, 134]. Therefore, it is possible 
that hydroxylation of K34 protects the PTM against promiscuous deacetylase CobB, 
but more research is necessary to verify the role of EpmC.  
4.3 Promiscuity of EpmA unlocks the enzyme’s potential 
In this study, EpmA was shown to activate non-natural α-, β-amino acids and lysine 
derivatives. Together with the knowledge on EpmA_A298G it can be made use of the 
intrinsic features and advantages of EpmA, EpmA_A298G and LysRS. The first is 
optimized for a β-amino acid, the second exhibits a similar catalytic pocket and 
favoured substrate than LysRS and the third serves for tRNA charging and therefore 
catalyzes the precursor step for incorporation of amino acids into peptides (Figure 34). 
During transition from the RNA world to establishment of the genetic code in the protein 
world, early aaRSs had to adapt specificity for their amino acids by shaping the binding 
pocket and reinforcing it with polar and nonpolar interaction partners [135]. Beside the 
canonical function of aaRS other novel and critical functions are described that 
illustrate evolutionary plurality and variability of aaRSs. Broad genome sequencing 
efforts revealed “footprints of aminoacyl-tRNA synthetases are everywhere”, so many 
enzymes include domains of aaRS which catalyze various reactions [136].  
 
Figure 34: Progression from aminoacyl-tRNA synthetase to EpmA with possible further 
developments. Although optimized for their cellular function (substrates shown in small font), a 
certain degree of substrate promiscuity is preserved during progression from aaRS to EpmA. 
Engineering of EpmA can lead to several future applications.  
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Among them are several examples of tRNA-binding domain truncated proteins [137–
139]. Ofir-Birin et al. described a transcriptional instead of translational role of LysRS 
in the human allergic response, represented by immune-stimulated mast cells [140]. 
Although aaRS act as potent protectors of the genetic code due to acceptor substrate 
specificity and editing ability He et al. demonstrated the ability of aaRSs to post-
translationally modify a lysine residue with amino acids [129, 141]. They modified the 
ε-terminal amino group of lysine within a peptide with all 20 amino acids in vitro, 
whereby each reaction was catalyzed by its corresponding aaRS. The addition of 
cognate tRNA was only necessary for attachment of arginine, glutamine or glutamic 
acid to lysine [129]. This demonstrates that aaRSs can deal with variable acceptor 
substrates, for example LysRS accepts a synthetic peptide instead of tRNALys.  
The evolution of EpmA can be backtracked to LysRS due to their homology. Conserved 
among these proteins are active site residues of the catalytic pocket, either involved in 
lysine or ATP recognition and binding [51]. Differences are lack of the aminoterminal 
anticodon binding domain and a replaced region of five amino acids following motif I 
[51]. An interesting approach that should be considered in the future traces back 
evolution to the point where the anticodon binding domain of LysRS was lost. Addition 
of this aminoterminal domain to EpmA could restore the capability of aminoacylating 
tRNALys (Figure 34). Even more striking it could be charged with (R)-β-lysine. Actual 
research in synthetic biology lays a strong focus on introduction of β-amino acids into 
a nascent protein chain. Here, the advantageous qualities of LysRS and EpmA can be 
combined to ultimately provide a versatile enzyme which unfolds its specificity for a β-
amino acid during the process of protein translation. 
Variation of EpmA’s catalytic pocket, in particular at the amino acid residue 298, had 
direct and comprehensible effect on donor substrate specificity. Backmutation of this 
residue to match the catalytic pocket of LysRS (G298) resulted in a clear preference 
for α-amino acids. In the future, further engineering of EpmA’s catalytic pocket 
optimizes substrate specificity toward other linear compounds with amino group. By 
formation of the aminoadenylate their reactivity is increased and chemical bond 
formation with the desired acceptor substrate is facilitated.  
It is demonstrated in this thesis, that EpmA is specific towards its acceptor substrate 
EF-P. The exchange of the central amino acid at the tip of the β3/β4 loop by arginine 
resulted in unmodified EF-P, even when epmA was overexpressed to support 
Discussion 
87 
 
substrate promiscuity. In this way, EpmA is shown to distinguish between K34 as 
cognate PTM position and another lysine residue at -3 position. Nevertheless, EpmA 
was shown to enlarge the spectrum of modification and introduces PTMs to side chains 
leaving the peptide terminus (site-selectivity) and other residues (chemoselectivity) 
unaltered. By that it has the potential to serve as a tool for synthetic biology demands. 
Further studies should focus on testing, adapting and applying EpmA to catalyze lysine 
modification of several relevant proteins or synthetic peptides instead of just EF-P as 
acceptor. By that the scope of application of EpmA broadens drastically. The 
derivatization of lysine in synthetic peptides is an actual task of synthetic biology 
because PTMs transform the folding and functional properties of proteins and unlock 
important regulation abilities. From the chemist’s point of view this is a challenge 
because the N-terminus and cysteine residues are more reactive due to their lower pKa 
values and nucleophilicities, respectively [142]. Commercially accessible peptides 
containing post-translationally modified lysine are only available with acetyl, malonyl, 
succinyl and methyl as modification (e. g. from JPT). EpmA can help to expand this 
spectrum and enable synthetic lysine modifications, for example in the so-called RiPPs 
(Ribosomally synthesized and post-translationally modified peptides). Especially the 
diversification of antimicrobial peptides can have wide therapeutic applications in the 
future [143]. Moreover, antibody-drug conjugates are often linked via lysine modifiers 
[144]. Exemplary applications are the lysine labeling of peptide hormone insulin and 
the eukaryotic peptide hormone analog octreotide with a fluorescent moiety or drug 
which was made possible by specifically modifying lysine with N-
phenylvinylsulfonamide derivatives [142]. Octreotide is a somatostatin analog that has 
been intensively used for conjugation with toxic drugs for targeted delivery into 
somatostatin receptor-selective cancer cells [142]. Lysine of insulin chain B is modified 
with a fatty acid (myristic acid or a C16-fatty acid) in the FDA approved drugs named 
detemir and degludec, respectively [142].  
Taken together, the promiscuity of EpmA unlocks its potential. It should be subject for 
engineering and directed evolution approaches to meet customized characteristics. 
Thereby, engineered EpmA variants can yield an enzyme capable of incorporation of 
β-amino acids, activation of non-natural amino acids, and modification of synthesized 
peptides. 
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4.4 Modification of EF-P in Bacillus 
This thesis shows that while EF-P was in the fully modified state during all growth 
phases of E. coli, EF-PB.s. separated in a denaturating horizontal IEF gel in unmodified 
and modified versions. Here, 59 – 88 % of EF-P was in the modified state. It can be 
speculated that the unresolved modification pathway in B. subtilis and other Firmicutes 
is not as efficient or not as fast as the EpmABC pathway, which is also indicated by 
the complexity of the unknown pathway that is postulated to include at least four 
different enzymes [36]. 
In this study different (predicted) aminotransferases were found to be potentially 
involved in the modification pathway. EF-Ps of B. subtilis ΔilvK, ΔepsN and ΔgsaB 
exhibited the same pI value than unmodified EF-P did. The latter strain was also 
examined by Witzky et al. with the same result [36]. Three of the 13 tested 
aminotransferase deletion strains exhibited reduced swarming motility, indicating an 
impaired EF-P modification pathway. Among them are B. subtilis ΔyhdR, Δdat and 
ΔyaaO. In the same way, swarming motility of B. subtilis Δefp is reported to be 
negatively affected compared to WT because diproline motifs - which are accumulated 
in flagellar genes - require functional EF-P for proper translation [34, 145]. 
Consequently, flagellar number is decreased in B. subtilis Δefp [110]. In addition, 
B. subtilis ΔymfI is unable to swarm due to the intermediate modification status of EF-P 
and accumulation of aminopentanone-modified EF-P [36]. Together with the results 
obtained by Witzky et al. [36], the hypothetical pathway, potential modification 
enzymes as well as influencing genes shown in Figure 35 can be derived.  
YmfI is reported to be the enzyme which catalyzes the final PTM step that is reduction 
of 5-aminopentanone to 5-aminopentanol [146]. Witzky et al. created a transposon 
mutagenized library of B. subtilis lacking the ymfI gene [36]. Interestingly, some genes 
they found to be transposon insertion suppressors of ymfI and therefore were able to 
swarm, were also found in this study by IEF analysis beforehand. B. subtilis ΔyaaO 
showed contradicting phenotypes in the two studies regarding swarming behavior and 
IEF band position. Witzky et al. suggested an indirect role of YaaO due to the fact that 
5-aminopentanolated EF-P is still found in this strain, admittedly in lower yield.  
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Figure 35: Post-translational modification of EF-P from B. subtilis. (A) Hypothetical pathway 
provided by Witzky et al. [36]. (B) Required genes for complete PTM found by Witzky et al. [36] 
(dark cloud) and in this study (light cloud). In addition, candidates with direct or indirect 
influence are listed.  
It was beyond the scope of this thesis to elucidate enzymes involved in the modification 
pathway of EF-P in Bacillus in detail. Nevertheless, candidates are presented that 
establish the basis for further studies. Those are added to ynbB, gsaB and ymfI which 
are believed to be involved in this pathway, as deletion of each of the genes abolished 
5-aminopentanolation of EF-P [36]. Moreover, it is likely that B. subtilis hydR, dat and 
yaaO are either directly involved in PTM of EF-P and thereby phenocopy B. subtilis 
Δefp, or indirectly influence EF-P or the pathway, or affect swarming motility in other 
ways.  
Analysis of EF-PB.s. during different phases showed that EF-P seemed to be 
underrepresented in low division phases like lag and stationary phase. Fittingly, 
B. subtilis was the first organism reported that does not exhibit a growth defect upon 
deletion of efp [34]. Despite its important role during translation, one should have in 
mind that efp is not essential in bacteria. The reason is, that translation of proline motifs 
is ten times faster in the presence of functional EF-P, nevertheless it is not completely 
abolished in absence of the translation factor [7]. Moreover, there are several other 
possible reasons for decreased translation speed such as occurrence of stalling 
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peptides like C-terminal proline residues, secretion monitor leader peptides (e. g. 
SecM) or stalling sequences like FXXYXIWPP and others, which induce programmed 
stalling during their own translation to regulate expression of downstream genes [21, 
147]. These regulatory programmed stalling incidents are explained by direct effects 
like encounter of polyproline motifs but also by indirect mechanisms like interactions 
of the nascent peptide with residues from the exit tunnel or the PTC [148, 149]. Here, 
positively charged stretches (lysine and arginine rich motifs) in the nascent peptide 
chain can interact with the negatively charged ribosomal exit tunnel when they are in 
10 - 20 Å distance from the PTC. Thereby, electrostatic interactions influence the 
translation rates [150]. Interestingly, nascent peptides that delay protein synthesis in 
bacteria are not rescued by EF-P [21]. Dependence on EF-P is lowered in phases of 
decreased general translation rates. Moreover, B. subtilis Δefp phenotype (swarming 
defect) suppressor strategies are reported like mutation of a stalling motif to decrease 
the translational pause (SPP mutated to APP in FliY) or mutation of genes involved in 
ribosome-associated factors and ribosomal proteins [110]. 
4.5 Detection of EF-P for elucidation of new post-translational 
modifications 
Methods for evaluation of PTMs which do not necessarily require an enrichment step 
are rare. In this thesis, two of those methods were provided and applied to EF-P 
(Chapters 3.1 and 3.2). It transpired that 1D-IEF is a suitable tool for modification status 
detection of EF-P and the method was successfully established in Prof. K. Jung 
laboratory during the practical work for this thesis. Consequently, the detailed IEF 
guideline in Table 8 summarizes the distinct applications of native horizontal, 
denaturating horizontal and vertical IEF. It includes information on sample preparation, 
gel treatment, resolution optimization and possible staining methods.  
Table 8: IEF techniques and their distinct applications. 
 Native horizontal IEF Denaturating horizontal IEF Vertical IEF 
Cross-
reference 
Chapters 2.6.3 and 
3.2.2 
Chapters 2.6.2, 2.6.4 and 3.4 
Chapters 2.6.5, 3.3.1 
and 3.3.3.3 
Application E. coli lysates B. subtilis lysates Purified proteins 
Sample 
preparation 
Wash/lysis: 10 mM Tris, 250 mM sucrose, pH 7.0  
 
Protein precipitation with 
TCA/acetone, resolve ON in 
solubilization mix 
 
Gel variant CleanGel IEF (GE) 
GE: CleanGel IEF  
SERVA: Blank FocusGel 24S 
SERVAGel IEF 4 - 7 
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Gel 
rehydration 
1.1 g D-sorbitol, 
820 µL Pharmalyte 4 -
6.5 ad 11 mL, 
incubate 1 h 
GE gel: solubilization mix 
without BPP, incubate ≥2 h  
Serva Gel: 12.84 g urea, 4.65 g 
thiourea, 2.46 mL Pharmalyte 4 
- 6.5, 1.28 g CHAPS, 0.32 g 
DTT ad 32 mL, incubate 2 h  
- 
Loading 
amount 
Lysates: 20 µL 
OD600=10 
Pure protein: 5 µg  
20 - 150 µg 1 µg 
Loading 
buffer 
10X: 50 v% glycerol, 
10 mg/mL BPP 
Not required  
(= solubilization mix) 
2X IEF Sample Buffer 
Running 
buffer 
- - 
SERVA IEF Anode 
Buffer + Cathode 
Buffer 3 - 10 
Sample 
application 
Large volume:  
filter paper next to 
cathode 
Small volume: directly 
Large volume: small filter paper 
stripe next to the cathode 
Small volume: silicone 
application strip 
Directly 
Temperature 10 °C 15 °C 4 °C 
Focusing 
conditions 
  
Prefocusing 350 V  6 mA  8 W, 20 min - 
Sample 
transition 
250 V  4 mA  8 W, 20 min 
50 V  10 mA  10 W, 
1 h 
Main focusing 1,000 V  7 mA  14 W, 4 h 
200 V  30 mA  10 W, 
1 h 
Band 
sharpening 
1,250 V  7 mA  18 W, 10 min 
500 V  40 mA 20 W, 
40 min 
Gel 
processing 
Remove gel from plastic film using a metal wire - 
Silver Staining or Western Blotting 
Coomassie/Silver 
Staining or Western 
Blotting 
    
Contrary to the hypothesized association, different descendants of the IEF technique 
(vertical / native horizontal / denaturating horizontal) were necessary for different 
organisms and sample types. Purified EF-P was easily detected by vertical IEF, native 
horizontal IEF was used to analyze lysates of Gram-negative E. coli. Gram-negative 
B. subtilis lysates required a preceding protein precipitation step with TCA/acetone 
before analysis by denaturating IEF. The gel was rehydrated using urea which leads 
to denaturating conditions, decreases the speed of separation by increasing gel 
viscosity [79] and at the same time claims a defined temperature management during 
gel processing.  
Unanticipatedly, protein tags caused a more drastic pI shift, than hypothesized based 
on the theoretical calculation. This was shown for His6- or SUMO-tagging. Also single 
amino acid exchanges like K34R and P32S affect the position of the band in the IEF 
gel. This practical issue was addressed by careful selection of the reference protein.  
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Establishing the IEF method and gaining expertise allowed useful insights into different 
aspects of EF-P research which were published by Pfab et al. [67], Pinheiro et al. [35] 
and Volkwein et al. [38]. It could be shown that endogenously and recombinantly 
produced EF-P from Corynebacterium glutamicum, Mycobacterium smegmatis and 
Steptomyces coelicolor exhibit the same pI value and are naturally unmodified [35]. 
Together with other Actinobacteria they form a new subfamily of EF-Ps which are 
functional without PTM. Research on switching the PTM of P. putida (rhamnosylation) 
to E. coli EF-P (naturally (R)-β-lysylated) included interaction studies with EarP from 
P. putida and EF-P from E. coli. Here, the technique of vertical IEF was used to ensure 
that EF-P was in the unmodified state to qualify it for the experiment. Subsequently, 
15N NMR relaxation experiments could be performed. Titration revealed facilitated 
interaction between the non-cognate PTM partners especially when K34 is exchanged 
by arginine to resemble the conserved residue of EF-P from P. putida (results 
published in [38]).  
The techniques of horizontal and vertical IEF presented in this thesis are not 
necessarily limited to EF-P or a specific PTM. Instead, the guideline for IEF of EF-P is 
generalizable for application to proteins from all domains of life. Therefore, the 
guideline contributes to microbiological methodology, especially in laboratories in 
which MS instruments are not available.  
Chapter 3.1 presents the creation, characterization and application of universal EF-P 
antibodies. Two amino acid sections of EF-P were identified which are highly 
conserved among different bacteria and accessible for an antibody at the same time. 
Corresponding peptide antibodies P68/P69 successfully detected EF-P of diversely 
shaped bacteria such as Gram-negative (E. coli, S. oneidensis) as well as Gram-
positive cocci (M. luteus), bacilli (B. subtilis) and filamentous bacteria (Streptomyces). 
At the same time the antibodies were specific, as a single band corresponding to EF-P 
was detected from bacterial lysates. 
Here, also copy number determination during different growth phases can be helpful, 
which was also demonstrated in this thesis. Determination of EF-P copy numbers was 
possible because the created EF-P antibodies showed a broad sector of linear 
correlation between band intensity and EF-P amount. In the same way that EF-P copy 
numbers per cell were determined for E. coli (7,360) and B. subtilis (6,717), they can 
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be derived for bacteria not equally well studied because literature values of EF-P copy 
numbers are rare. 
Juxtaposition of P68 and P69 during antibody characterization revealed that P69 was 
slightly more sensitive than P68 regarding E. coli and S. oneidensis. Comparison of 
the sequence identity of the three model organisms with the peptide sequence used 
for rabbit immunization and antibody purification was performed in Table 9. It shows 
that the raw numbers of sequence identity do not necessarily explain this fact and also 
not why EF-PS.o. was undetectable from lysate but needed to be concentrated prior to 
SDS-PAGE and Western Blot analysis. For example, EF-PB.s. was sensitively detected 
by P69 (53 % sequence identity), whereas EF-PS.o. was hard to detect using P68 (60 % 
sequence identity). Therefore, sensitivities of the universal antibodies for bacterial 
EF-Ps are not predictable and should be tested individually. Optimal conditions 
(antibody, dilution and incubation time) determined for standard organisms are listed 
in Table 9.   
Table 9: Sequence identity between peptide antibodies P68/P69 and model organism EF-Ps. 
Theoretical sequence identity between antibody peptide and EF-P sequence do not inevitably 
represent antibody effectivity. Antibody characterization results and final antibody usage 
suggestions are summarized in the right column.  
 Theoretical result Experimental 
result/ 
Recommendation  Peptide antibody P68 Peptide antibody P69 
Peptide 
sequence 
NH2- C+ 
TEPGVKGDTAGGTKP 
-CONH2 
NH2- C+ 
VPLFINEGEKIKVDT 
-CONH2 
 
EF-P sequence 
(% identity) 
   
E. coli  
DPGLKGDTAGTGGKP 
(73 %) 
VPLFVQIGEVIKVDT 
(73 %) 
P69 ON 1:1,000 
B. subtilis  
TEPGIKGDTASGGTKP 
(93 %) 
VPFFVNEGDTLVVNT 
(53 %) 
Very sensitive,  
Mix 1:10,000 
S. oneidensis  
EPSARGDTSGKVMKP 
(60 %) 
VADFVKVGDKIEIDT 
(47 %) 
Only for purified 
proteins > 0.25 μg  
P69 1:1,000 ON 
 
The spectrum of EF-P antibodies is broadened. Antibodies are located on the one side 
of the spectrum that were raised against the PTM as single epitope (anti-EF-PRha [39, 
41], anti-acetyllysine ([151], now commercially available, e. g. ImmuneChem), anti-
propionyllysine [152], anti-butyryllysine (commercially available, e. g. PTM Biolabs), 
anti-succinyllysine [153]). Despite their advantages, they only provide a yes-or-no 
answer regarding the modification status and are inconvenient tools to identify novel 
Discussion 
94 
 
PTMs and novel modified sites by immunoblotting. For model organisms like E. coli, 
S. oneidensis, B. subtilis or T. thermophilus antibodies are available that detect the 
native protein. The cross-reactivity of B. subtilis EF-P antibody with Mycobacterium 
phlei EF-P is ascertained by our group (unpublished) and the detection of Neisseria 
meningitides EF-P is reported using a polyclonal E. coli EF-P antibody purchased from 
Keari Bio [154]. On the other side of the spectrum is the universal EF-P antibody 
reported here, that serves as elegant tool for analysis of diverse EF-Ps without 
necessitating a protein enrichment step.  
Further studies should consider that immunoprecipitation is a centerpiece technique of 
PTM analysis because here, low-abundant proteins with PTM are targeted and 
enriched. Therefore, antibodies that specifically bind the target protein or PTM are 
conjugated to solid beads and enable affinity purification. The universal EF-P antibody 
presented in this study can be used in immunoprecipitation to enrich EF-P from 
different bacteria not sufficiently addressed to date.  
EF-P modification enzymes are predominantly unknown in Gram-positive bacteria for 
which P68/P69 performs particularly well. There is also only little research on the 
archaeal ortholog of EF-P, but it was shown that archaeal translation initiation factor 
5A (aIF5A) of the crenarchaeum Sulfolobus solfataricus forms complexes with 
deoxyhypusine synthase and is modified with hypusine just like the eukaryotic 
representative eIF5A [30]. Interestingly it was found that besides its activity in protein 
synthesis aIF5A also exhibits moonlighting function in RNA metabolism as it exhibits 
endoribonucleolytic activity [155]. Moonlighting describes the ability of a protein to bear 
more than one physiological function. This distinct activity is often applied in different 
places or times and must not originate from genetic fusion, splice variants or 
fragmentation [52]. Moonlighting and promiscuity are opposed, as the latter is defined 
by performance of a physiologically irrelevant secondary reaction. The newly available 
antibodies P68/P69 detect EF-P independent of its modification status and can 
therefore be used to study possible new functions of EF-P or its potential regulatory 
role in unstudied strains. 
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